

No. 2024-1137

United States Court of Appeals
for the Federal Circuit

INSULET CORPORATION,

Plaintiff-Appellee,

v.

EOFlow Co., LTD.; EOFlow, INC.,

Defendants-Appellants,

—and—

STEVEN DIANNI; LUIS J. MALAVE; IAN G. WELSFORD; JESSE J. KIM; FLEXTRONICS
MEDICAL SALES AND MARKETING LTD.;

Defendants.

On Appeal from the United States District Court
for the District of Massachusetts (No. 1:23-cv-11780-FDS) (Saylor, J.)

DEFENDANTS-APPELLANTS' OPENING BRIEF

LOWELL D. MEAD
COOLEY LLP
3175 Hanover Street
Palo Alto, CA 94304

ADAM S. GERSHENSON
KIMBERLEY A. SCIMECA
COOLEY LLP
500 Boylston Street
Boston, MA 02116
(617) 937-2300

ELIZABETH M. FLANAGAN
COOLEY LLP
30 S. 9th Street, 7th Floor
Minneapolis, MN 55402

PATRICK J. HAYDEN
COOLEY LLP
55 Hudson Yards
New York, NY 10001

Counsel for Defendants-Appellants EOFlow Co., Ltd. and EOFlow, Inc.

CERTIFICATE OF INTEREST

Counsel for EOFlow defendants, Adam S. Gershenson, certifies the following:

1. **Represented Entities.** Provide the full names of all entities represented by undersigned counsel in this case. Fed. Cir. R. 47.4(a)(1).

EOFlow Co., Ltd.; EOFlow, Inc.

2. **Real Party in Interest.** Provide the full names of all real parties in interest for the entities. Do not list the real parties if they are the same as the entities. Fed. Cir. R. 47.4(a)(2).

Not applicable.

3. **Parent Corporations and Stockholders.** Provide the full names of all parent corporations for the entities and all publicly held companies that own 10% or more stock in the entities. Fed. Cir. R. 47.4(a)(3).

EOFlow Co., Ltd.

4. **Legal Representatives.** List all law firms, partners, and associates that (a) appeared for the entities in the originating court or agency or (b) are expected to appear in this court for the entities. Do not include those who have already entered an appearance in this court. Fed. Cir. R. 47.4(a)(4).

Michael Sheetz; Quinn Emanuel Urquhart & Sullivan; Patrick Daniel Curran; Nathaniel Andrew Hamstra; Stacylyn May Doore; William D. Weinreb.

5. **Related Cases.** Provide the case titles and numbers of any case known to be pending in this court or any other court or agency that will directly affect or be directly affected by this court's decision in the pending appeal. Do not including the originating case number(s) for this case. Fed. Cir. R. 47.4(a)(5).

Not applicable.

- 6. Organizational Victims and Bankruptcy Cases.** Provide any information required under Fed. R. App. P. 26.1(b) (organizational victims in criminal cases) and 26.1(c) (bankruptcy case debtors and trustees). Fed. Cir. R. 47.4(a)(6).

Not applicable.

Dated: December 4, 2023

/s/ Adam S. Gershenson

Adam S. Gershenson

TABLE OF CONTENTS

	Page
PRELIMINARY STATEMENT	1
JURISDICTIONAL STATEMENT	3
STATEMENT OF THE ISSUES.....	4
STATEMENT OF THE CASE.....	4
I. Factual Background.....	4
A. Insulet Produces an Insulin Pump Called the Omnipod.	4
B. EOfFlow Produces an Insulin Pump Called the EOPatch.....	5
C. Despite Knowing EOfFlow Had Designed a Patch Pump and Hired Former Insulet Employees, Insulet Failed to Take Any Steps to Protect Its Alleged Trade Secrets for Over Five Years.....	8
II. Procedural Background	13
SUMMARY OF THE ARGUMENT	17
STANDARD OF REVIEW	19
ARGUMENT	20
I. The District Court Erred in Analyzing Success on the Merits Because It Ignored and Misapplied Trade Secret Law.	20
A. Reversal Is Warranted Because Insulet’s Claim Is Untimely, and the District Court Failed to Analyze the Statute of Limitations.	21
B. The District Court Erred in Concluding That the Information at Issue Qualified for Trade Secret Protection.	25
C. The District Court Erred in Finding Misappropriation.	42
II. Insulet Failed to Show a Significant Risk of Irreparable Harm.	46
A. Insulet Is Not Entitled to Emergency Relief Because It Did Not Treat	

TABLE OF CONTENTS
(continued)

	Page
the Alleged Theft of Its Trade Secrets as an Emergency.....	47
B. Insulet Does Not Face Any Imminent Harm Warranting Preliminary Relief.	51
III. The Balance of the Equities and the Public Interest Weigh Against Preliminary Injunctive Relief.	55
CONCLUSION.....	59

TABLE OF AUTHORITIES

	Page(s)
 Cases	
<i>Abbott Lab’ys v. Andrx Pharm., Inc.</i> , 452 F.3d 1331 (Fed. Cir. 2006)	52
<i>Abbott Lab’ys v. Brennan</i> , 952 F.2d 1346 (Fed. Cir. 1991)	4
<i>Abbott Lab’ys v. Selfcare, Inc.</i> , 17 F. Supp. 2d 43 (D. Mass. 1998).....	50
<i>Abrasic 90 v. Weldcote Metals</i> , 364 F. Supp. 3d 888 (N.D. Ill. 2019).....	36
<i>Aggreko, LLC v. Koronis</i> , 2013 WL 6835165 (D. Mass. Dec. 19, 2013).....	44
<i>Allscripts Healthcare, LLC v. DR/Decision Res., LLC</i> , 386 F. Supp. 3d 89 (D. Mass 2019).....	42
<i>Alpha Pro Tech, Inc. v. VWR Int’l, LLC</i> , 2017 WL 3671264 (E.D. Pa. Aug. 23, 2017)	38
<i>Am. Inst. for Foreign Study, Inc. v. Fernandez-Jimenez</i> , 468 F. Supp. 3d 414 (D. Mass. 2020).....	32
<i>Am. Sci. & Eng’g, Inc. v. Kelly</i> , 69 F. Supp. 2d 227 (D. Mass. 1999).....	44
<i>Amgen Inc. v. Sanofi</i> , 872 F.3d 1367 (Fed. Cir. 2017)	57
<i>AnywhereCommerce, Inc. v. Ingenico Inc.</i> , 2023 WL 2694043 (D. Mass. Mar. 29, 2023)	24, 25
<i>Arborjet, Inc. v. Rainbow Treecare Sci. Advancements</i> , 794 F. 3d 168 (1st Cir. 2015).....	55

TABLE OF AUTHORITIES

(continued)

	Page(s)
<i>Arconic Corp. v. Novelis Inc.</i> , 2021 WL 4479484 (W.D. Pa. Sept. 30, 2021).....	29
<i>Beane v. Beane</i> , 856 F. Supp. 2d 280 (D. Mass. 2012).....	29
<i>Blake v. Pro. Coin Grading Serv.</i> , 898 F. Supp. 2d 365 (D. Mass. 2012).....	40
<i>Bonito Boats, Inc. v. Thunder Craft Boats, Inc.</i> , 489 U.S. 141 (1989).....	37, 38
<i>Bos. Heart Diagnostics Corp. v. Health Diagnostics Lab’y, Inc.</i> , 2014 WL 2048436 (D. Mass. May 16, 2014).....	57
<i>Bos. Parent Coal. For Acad. Excellence Corp. v. Sch. Comm. Of City of Bos.</i> , 996 F.3d 37 (1st Cir. 2021).....	56
<i>Bridgeview Bank Grp. v. Meyer</i> , 49 N.E.3d 916 (Ill. App. 2016).....	53
<i>Broad-Ocean Techs., LLC v. Lei</i> , 2023 WL 145001 (E.D. Mich. Jan. 9, 2023)	31
<i>Cablevision of Bos., Inc. v. Pub. Imp. Comm’n of City of Bos.</i> , 38 F. Supp. 2d 46 (D. Mass. 1999).....	59
<i>Campbell Soup Co. v. ConAgra, Inc.</i> , 977 F.2d 86 (3d Cir. 1992)	53
<i>Channing Bete Co., Inc. v. Greenberg</i> , 2021 WL 4691597 (D. Mass. July 12, 2021)	49
<i>Charlesbank Equity Fund II v. Blinds To Go, Inc.</i> , 370 F.3d 151 (1st Cir. 2004).....	47, 49, 54
<i>Cinebase Software, Inc. v. Media Guar. Tr., Inc.</i> , 1998 WL 661465 (N.D. Cal. Sept. 22, 1998).....	45

TABLE OF AUTHORITIES

(continued)

	Page(s)
<i>City of Lowell v. Enel N. Am., Inc.</i> , 705 F. Supp. 2d 116 (D. Mass. 2010).....	41
<i>CMI Roadbuilding, Inc. v. Iowa Parts, Inc.</i> , 920 F.3d 560 (8th Cir. 2019)	24, 25
<i>Concrete Mach. Co. v. Classic Lawn Ornaments, Inc.</i> , 843 F.2d 600 (1st Cir. 1988).....	20
<i>CVD, Inc. v. Raytheon Co.</i> , 769 F.2d 842 (1st Cir. 1985).....	33, 40
<i>Dynamics Rsch. Corp. v Analytic Scis. Corp.</i> , 400 N.E.2d 1274 (Mass. App. Ct. 1980)	29, 35
<i>Epstein v. C.R. Bard, Inc.</i> , 460 F.3d 183 (1st Cir. 2006).....	25
<i>Ezold v. Wolf, Block, Schorr & Solis-Cohen</i> , 983 F.2d 509 (3d Cir. 1992)	42
<i>Flotec, Inc. v. S. Rsch., Inc.</i> , 16 F. Supp. 2d 992 (S.D. Ind. 1998).....	45
<i>Freeman Inv. Mgmt. Co. v. Frank Russell Co.</i> , 2016 WL 5719819 (S.D. Cal. Sept. 30, 2016).....	30
<i>Fritz v. Arthur D. Little, Inc.</i> , 944 F. Supp. 95 (D. Mass. 1996).....	52
<i>Gonzalez v. Real Time Resols., Inc.</i> , 2019 WL 7596277 (D.N.H. Aug. 29, 2019).....	22
<i>Grease Monkey Int’l, Inc. v. Ralco Lubrication Servs., Inc.</i> , 24 F. Supp. 2d 120 (D. Mass. 1998).....	57
<i>Green Earth Energy Photovoltaic Corp. v. KeyCorp</i> , 2020 WL 1816379 (D. Mass. Jan. 10, 2020).....	32

TABLE OF AUTHORITIES

(continued)

	Page(s)
<i>Hardwire, LLC v. Freyssinet Int’l Et Cie</i> , 2023 WL 1819321 (E.D.N.Y. Feb. 8, 2023)	22
<i>Harvard Apparatus, Inc. v. Cowen</i> , 130 F. Supp. 2d 161 (D. Mass 2001)	43
<i>HiRel Connectors, Inc. v. United States</i> , 2005 WL 4958547 (C.D. Cal. Jan. 4, 2005)	34
<i>I.P. Lund Trading ApS v. Kohler Co.</i> , 163 F.3d 27 (1st Cir. 1998)	19, 27
<i>iAlamar Biosciences, Inc. v. Difco Lab’ys, Inc.</i> , 1995 WL 912345 (E.D. Cal. Oct. 13, 1995)	34
<i>ICU Med. Inc. v. Alaris Med. Sys., Inc.</i> , 2004 WL 1874992 (C.D. Cal. July 30, 2004)	58
<i>IDX Sys. Corp. v. Epic Sys. Corp.</i> , 285 F.3d 581 (7th Cir. 2002)	29
<i>Imax Corp. v. Cinema Techs., Inc.</i> , 152 F.3d 1161 (9th Cir. 1998)	26, 39
<i>Kerrissey v. Com. Credit Grp., Inc.</i> , 359 F. Supp. 3d 151 (D. Mass. 2019)	54
<i>Kewanee Oil Co. v. Bicron Corp.</i> , 416 U.S. 470 (1974)	37, 38
<i>Knights Armament Co. v. Optical Sys. Tech., Inc.</i> , 654 F.3d 1179 (11th Cir. 2011)	24
<i>KPM Analytics N. Am. Corp. v. Blue Sun Sci., LLC</i> , 2021 WL 2982866 (D. Mass. July 15, 2021)	21
<i>Lamb-Weston, Inc. v. McCain Foods, Ltd.</i> , 941 F.2d 970 (9th Cir. 1991)	53

TABLE OF AUTHORITIES

(continued)

	Page(s)
<i>Loc. 507, Transp. Workers Union of Am., AFL-CIO v. Transp. Workers Union of Am., AFL-CIO,</i> 2001 WL 92161 (D. Mass. Jan. 12, 2001).....	50
<i>Macchione v. Coordinator Adm’r,</i> 591 F. App’x 48 (3d Cir. 2014) (unpublished).....	51, 54
<i>Matos v. Clinton Sch. Dist.,</i> 367 F.3d 68 (1st Cir. 2004).....	51
<i>McDonough v. Trs. of Univ. Sys. of New Hampshire,</i> 704 F.2d 780 (1st Cir. 1983).....	41
<i>Media3 Techs., LLC v. Mail Abuse Prevention Sys., LLC,</i> 2001 WL 92389 (D. Mass. Jan. 2, 2001).....	50
<i>Medtronic MiniMed, Inc. v. Nova Biomedical Corp.,</i> 2008 WL 11338115 (C.D. Cal. May 14, 2008).....	58
<i>MGA Ent., Inc. v. Mattel, Inc.,</i> 41 Cal. App. 5th 554 (2019)	24
<i>Momenta Pharms., Inc. v. Amphastar Pharms., Inc.,</i> 686 F.3d 1348 (Fed. Cir. 2012)	20
<i>Neural Magic, Inc. v. Facebook, Inc.,</i> 2020 WL 13819257 (D. Mass. May 29, 2020).....	41, 42
<i>Neural Magic, Inc. v. Meta Platforms, Inc.,</i> 2023 WL 2383172 (D. Mass. Mar. 6, 2023)	26, 33
<i>Nova Design Techs. v. Walters,</i> 875 F. Supp. 2d 458 (E.D. Pa. 2012).....	44
<i>Nutrition 21 v. United States,</i> 930 F.2d 867 (Fed. Cir. 1991)	19
<i>NuVasive, Inc. v. Day,</i> 954 F.3d 439 (1st Cir. 2020).....	46

TABLE OF AUTHORITIES

(continued)

	Page(s)
<i>Oxford Immunotec Ltd. v. Qiagen, Inc.</i> , 271 F. Supp. 3d 358 (D. Mass. 2017).....	51
<i>Pie Dev., LLC v. Pie Ins. Holdings, Inc.</i> , 2023 WL 2707184 (5th Cir. Mar. 30, 2023) (per curiam) (unpublished)	34
<i>RE/MAX of New England, Inc. v. Prestige Real Estate, Inc.</i> , 2014 WL 3058295 (D. Mass. July 7, 2014)	57
<i>Respect Maine PAC v. McKee</i> , 622 F.3d 13 (1st Cir. 2010).....	56
<i>In re Search Warrant Issued June 13, 2019</i> , 942 F.3d 159 (4th Cir. 2019), <i>as amended</i> (Oct. 31, 2019).....	42
<i>Sierra Club v. Larson</i> , 769 F. Supp. 420 (D. Mass. 1991).....	51
<i>Skarzynski v. U.S. Bank NA</i> , 2018 WL 2247240 (D. Mass. May 16, 2018).....	22
<i>SoClean, Inc. v. Sunset Healthcare Sols., Inc.</i> , 52 F.4th 1363 (Fed. Cir. 2022)	19
<i>Spencer Cos., Inc. v. Armonk Indus., Inc.</i> , 489 F.2d 704 (1st Cir. 1973).....	41
<i>Sutra, Inc. v. Iceland Exp.</i> , <i>ehf</i> , 2008 WL 2705580 (D. Mass. July 10, 2008)	40
<i>Synopsys, Inc. v. Risk Based Sec., Inc.</i> 70 F.4th 759 (4th Cir. 2023)	30
<i>Teradata Corp. v. SAP SE</i> , 2023 WL 4882885 (Fed. Cir. Aug. 1, 2023)	30, 32, 43
<i>TLS Mgmt. & Mktg. Servs., LLC v. Rodríguez-Toledo</i> , 966 F.3d 46 (1st Cir. 2020).....	26, 31, 42

TABLE OF AUTHORITIES (continued)

	Page(s)
<i>Town & Country Linen Corp. v. Ingenious Designs LLC</i> , 556 F. Supp. 3d 222 (S.D.N.Y. 2021)	45
<i>Ultimax Cement Mfg. Corp. v. CTS Cement Mfg. Corp.</i> , 587 F.3d 1339 (Fed. Cir. 2009)	40
<i>United States v. Booz Allen Hamilton Inc.</i> , 2022 WL 16553230 (D. Md. Oct. 31, 2022)	53
<i>United States v. Hooe</i> , 7 U.S. (3 Cranch) 73 (1805)	32
<i>United Steelworkers of Am., AFL-CIO-CLC v. Auchter</i> , 763 F.2d 728 (3d Cir. 1985)	38
<i>Vascular Sols. LLC v. Medtronic, Inc.</i> , 2020 WL 1809195 (D. Minn. Apr. 9, 2020).....	58
<i>Virginia Carolina Tools, Inc. v. International Tool Supply, Inc.</i> , 984 F.2d 113 (4th Cir. 1993)	56
<i>Vita Int’l, Inc. v. Foro Energy, Inc.</i> , 2022 WL 350195 (S.D. Tex. Jan. 4, 2022).....	31
<i>Voice of the Arab World, Inc. v. MDTV Med. News Now, Inc.</i> , 645 F.3d 26 (1st Cir. 2011).....	46, 47
<i>Walker Mfg., Inc. v. Hoffmann, Inc.</i> , 261 F. Supp. 2d 1054 (N.D. Iowa 2003)	38
<i>Warren Freedensfeld Assocs., Inc. v. McTigue</i> , 531 F.3d 38 (1st Cir. 2008).....	22
<i>Welter v. Med. Pro. Mut. Ins. Co.</i> , 2023 WL 2988627 (D. Mass. Feb. 23, 2023)	28
<i>Winnett v. Caterpillar, Inc.</i> , 609 F.3d 404 (6th Cir. 2010)	1, 22

TABLE OF AUTHORITIES (continued)

	Page(s)
<i>Winter v. NRDC, Inc.</i> , 555 U.S. 7 (2008).....	19, 51, 55
<i>World Gym, Inc. v. Baker</i> , 474 F. Supp. 3d 426 (D. Mass. 2020).....	59
<i>Zirvi v. Flatley</i> , 433 F. Supp. 3d 448 (S.D.N.Y. 2020)	26
<i>Zirvi v. Flatley</i> , 838 F. App'x 582 (2d Cir. 2020)	25
 Statutes	
18 U.S.C. § 1836.....	20, 21
§ 1839.....	<i>passim</i>
28 U.S.C. § 1292.....	4
§ 1331.....	3
§ 1338.....	3
§ 1367.....	3
 Other Authorities	
11A Charles Alan Wright, Arthur R. Miller & Mary Kay Kane, <i>Federal Practice and Procedure</i> (3d ed. 2023).....	46

STATEMENT OF RELATED CASES

No other appeal from the same underlying proceeding was previously before this or any other appellate court.

Appellants are unaware of any case that will directly affect or be directly affected by this Court's decision in the present appeal.

PRELIMINARY STATEMENT

This is an interlocutory appeal of a preliminary injunction awarded in a Defend Trade Secrets Act (“DTSA”) case that contravenes first principles of injunctive relief and trade secret law. The district court committed multiple legal errors, any one of which independently warrants reversal.

First, the district court erred in holding that Plaintiff-Appellee Insulet Corp. (“Insulet”) was likely to succeed on the merits without performing the analysis required by law. This case should have been easily resolved on statute of limitations grounds alone: the DTSA has a three-year statute of limitations, and Insulet was indisputably on inquiry notice that Defendants-Appellees EOFlow Co., Ltd. and EOFlow, Inc. (“EOFlow”) had developed a “strikingly similar” product more than *five years* before Insulet filed this suit. Appx97. “[T]ime-barred claims necessarily have no chance of success.” *Winnett v. Caterpillar, Inc.*, 609 F.3d 404, 408 (6th Cir. 2010). Remarkably, the district court did not even address this dispositive issue—it “express[ed] no opinion about the accrual of the statute of limitations” and announced, “[t]hat’s not the issue here.” Appx15. Ignoring the clear untimeliness of Insulet’s claim, the district court focused almost exclusively on a set of old, ostensibly “confidential” materials retained by ex-employees, and proceeded to make a series of other legal errors—including by failing to adequately assess whether Insulet had actually demonstrated the existence of any trade secrets, or

whether any of those secrets had been misappropriated.

Second, the district court erred in holding that Insulet faced imminent irreparable harm simply because another company, Medtronic plc, was poised to invest in EOFlow and could one day compete with Insulet—a commercial development distinct from any misappropriation that might have occurred half a decade before. But Insulet could not claim any imminent irreparable harm, including because it had known for *years* that EOFlow had developed a competing product and hired several of its former employees, held discussions with EOFlow about collaborations, and received EOFlow’s materials comparing the companies’ two products. The harm that Insulet now invokes, and which the district court improperly deemed irreparable, is not the acquisition, use, or disclosure of trade secrets—which Insulet alleges happened years ago—but instead merely a commercial transaction that might cost Insulet money if Medtronic were to one day sell EOFlow’s product. But neither fear of a larger competitor nor any theoretical, far-off sales that would come (if ever) after this case concludes and could be readily calculated and remedied with money damages, is cognizable irreparable harm.

Third, the district court failed to analyze, much less balance, the harm an injunction would inflict on EOFlow—a threat to its very existence—and neglected the public’s interest in choosing between competing medical devices and promoting access to essential medical treatments. Any one of these errors warrants reversal.

This is not a case of a thorough, written opinion containing a stray or harmless mistake. The district court issued *no* written opinion and cited *no* trade secrets case law. Instead, the district court gave a bench ruling that remarkably embraced the view that a trade secret claimant need not take any timely action to protect its purported secrets—not even a cease-and-desist letter, or a reminder-of-obligations to former employees—but can instead lie in wait and secure emergency relief *many years* after the duty kicks in to investigate a potential trade secret claim, all to eliminate the purported threat of increased competition.

If left to stand, the district court’s ruling would turn trade secret law on its head and render injunctive relief an ordinary remedy rather than the extraordinary remedy that the law deems it. The district court’s order should be reversed.

JURISDICTIONAL STATEMENT

The district court has subject matter jurisdiction over Plaintiff’s federal claims pursuant to 28 U.S.C. § 1331 & 1338(a), and supplemental jurisdiction over Plaintiff’s state law claims pursuant to 28 U.S.C. § 1367.

On October 6, 2023, the district court entered the preliminary injunction order. Appx35–37. EOFlow’s Motion for Modification or Clarification of Preliminary Injunction followed. ECF No. 130.¹ On October 24, 2023, the district court

¹ “ECF No.” refers to docket entries in the district court proceeding, Case No. 1:23-cv-11780-FDS (D. Mass.).

amended the preliminary injunction. Appx38–41. On November 6, 2023, EOFlow timely filed a notice of appeal. Appx7873.

This Court has jurisdiction pursuant to 28 U.S.C. § 1292(a)(1) & (c)(1); *see also Abbott Lab’ys v. Brennan*, 952 F.2d 1346, 1349-50 (Fed. Cir. 1991) (“The path of appeal is determined by the basis of jurisdiction in the district court, and is not controlled by the district court’s decision or the substance of the issues that are appealed.”).

STATEMENT OF THE ISSUES

Should this Court reverse the district court’s decision granting Insulet a preliminary injunction, where the district court’s analysis was marred by legal errors, including the failure to evaluate the applicable statute of limitations, consider the factors relevant to determining what constitutes a trade secret, and meaningfully evaluate the balance of harms and public interest?

STATEMENT OF THE CASE

I. Factual Background

Insulet and EOFlow are both medical device manufacturers. Both companies have developed their own insulin pump patches, which deliver life-saving insulin to diabetes patients.

A. Insulet Produces an Insulin Pump Called the Omnipod.

In 2002, Insulet began developing the Omnipod, a disposable, wearable insulin pump. Roughly three years later, in 2005, Insulet received FDA 510(k) premarket approvals and began marketing the Omnipod. Appx228, Appx952–67, Appx941–42, Appx944. Insulet then decided to update the Omnipod to a version called “Eros” in 2008, obtained 510(k) approval for the product in December 2012, and commercially launched it in the United States in 2013. Appx202–03.

The Omnipod device and all its components are, and have always been, publicly available. The device is sold with no End User License Agreement or any other restriction on use. Accordingly, the Omnipod has been “torn down” many times, with multiple parties posting videos and publishing detailed analyses of its inner workings. Appx822. And as early as 2010, Insulet itself published details on Omnipod’s schematics, “under-the-hood” photographs, and technical specifications. Appx974–89.

B. EOFlow Produces an Insulin Pump Called the EOPatch.

In 2011, Jesse Kim, a graduate of MIT and an engineer by trade and training, founded EOFlow. Kim had licensed a patent for electro-osmotic pump technology and set forth to harness it to create a superior insulin pump for diabetes patients. Appx1747; Appx1753. EOFlow initially raised \$70 million, which it poured into R&D. Appx1747. Kim recruited a team of sophisticated engineers to begin developing the Company’s flagship product, the “EOPatch” diabetes pump. *Id.*;

Appx710. The most essential and complex aspect of any diabetes patch pump is the actuator, which controls the component parts' movement and the delivery of insulin. Appx1747. EOFlow's actuator is (a) indisputably *unlike* the Omnipod's, and (b) based on in-licensed technology. *See, e.g.*, Appx16 (district court recognizing that EOFlow's "actuator [] is different from Insulet's actuator"); Appx25 (Insulet seeking an injunction only on "those components sort of downstream from the actuator").

In 2017, EOFlow won regulatory approval for its first wearable insulin pump patch, the EOPatch 1, which was developed by its Korea-based team. Appx1712; Appx1125. EOFlow's engineers then began developing the next-generation EOPatch, Version 2. Appx942. Those engineers, who came from leading consumer electronics companies, leveraged existing components from EOPatch 1, including the electro-osmotic pump, a part of the reservoir sub-assembly, and polycarbonate housing material. Appx1826–27; Appx833. They also designed anew other components based on lessons learned from EOPatch 1 and incorporated certain design plans initially meant for EOPatch 1. Appx943; Appx1712.

At all stages, EOFlow's design efforts used publicly available information on competing products like Omnipod. Starting in 2014, EOFlow purchased, tore down, and reverse engineered multiple Omnipod devices. *See* Appx4555–600. This

informed the design of EOFlow components such as its gear module shaft, rotational spring sensors, and fill sensing mechanism. *See, e.g.*, Appx4556–600.

In addition, during the development of EOPatch 2, in 2017 and 2018, Defendants Luis Malave, Ian Welsford, and Steven DiIanni each joined EOFlow, bringing their years of industry experience, including at Insulet, to help EOFlow expand its business. Appx804. These Individual Defendants provided business development and regulatory advice, as well as their general knowledge and expertise in the medical device industry; none of them drove the design or manufacturing processes for EOPatch 2. Appx215–16; Appx1852; Appx2013; Appx2017; Appx1879–80.

In June 2019, EOFlow won a second regulatory approval for EOPatch 2. Appx1747. But even with the benefit of reverse engineering, this was not a swift, cheap, or overnight process; more work ensued before commercial launch. Instead, and contrary to the one-sided portrayal by the district court, EOFlow’s team in Korea diligently developed the product for years separate from the limited input provided by the ex-Insulet individuals in the United States. EOFlow revised its technical specifications at least ten times before launching in April 2021—almost three-and-a-half years after EOPatch 2 work began. *Id.*

EOFlow is currently distributing EOPatch 2 in select Asian and European markets. Any distribution in the United States is, at a minimum, several years in the future, and requires FDA approval as a predicate. Appx1750.

In February 2023, industry news outlets reported that Medtronic had started a diligence process to acquire EOFlow. Appx1072–75. On May 23, 2023, Medtronic and EOFlow formally announced an agreement to acquire EOFlow stock on the Korean stock exchange. Appx1080–84.

C. Despite Knowing EOFlow Had Designed a Patch Pump and Hired Former Insulet Employees, Insulet Failed to Take Any Steps to Protect Its Alleged Trade Secrets for Over Five Years.

Given the value trade secrets may impart, both law and logic dictate that businesses must act swiftly to protect any such secrets from potential misappropriation. Insulet did nothing of the kind. Over five years elapsed after Insulet first learned in 2018 that EOFlow had developed an insulin patch pump and employed at least Insulet’s former head of R&D, yet Insulet did not act to protect its supposed trade secrets until 2023. Over those five years, Insulet communicated frequently with EOFlow; tracked EOFlow’s progress online; received presentations directly from EOFlow about its competing product; and contemplated buying EOFlow; but never even *mentioned* to EOFlow or any Individual Defendant any concern about any trade secret. Insulet never raised any such concern until 2023,

when after years of hard work and investment, EOFlow stood on the verge of being acquired by Medtronic.

1. 2018 Trade Show

In 2018, an Insulet engineer (and now VP of Product), Jason O'Connor, spoke to Luis Malave, Insulet's former head of R&D, at an American Diabetes Association ("ADA") conference and learned Malave was working for EOFlow. Appx2104. At that same conference, EOFlow displayed EOPatch devices, including a transparent version of the EOPatch 2. *See* Appx2038–39; Appx1750; Appx1752. Insulet's head of R&D, Eric Benjamin, visited EOFlow's booth at the conference and concluded the EOPatch and Insulet's Omnipod shared a "stunning resemblance." Appx1059–61. Yet Insulet took no action to investigate any potential trade secret misappropriation.


2. 2019 Overview of EOFlow

In March 2019, Insulet's then-VP of Strategy and Corporate Development contacted Malave requesting a further "overview of EOFlow." Appx1065–68. This discussion did not involve Insulet requesting an EOPatch or asserting a trade secret claim; instead, Insulet raised an opportunity for "potential collaboration between the two companies" and inquired about "the plans that [EOFlow] ha[d] for the company." Appx2110–11.

3. 2021–2022 Technical Analyses, Collaboration Discussions, and Investor Presentations

In March and April 2021—within three years after learning of EOPatch—Insulet conducted detailed technical analyses of the EOPatch and Omnipod, comparing them across 24 parameters, including size, weight, cannula material, and insertion mechanism, and noting the similarities and differences in the length and thickness of the products’ component parts. Appx2272; Appx2290; Appx2307. And, despite learning around this time that EOPatch 2 could be purchased online in Korea without a prescription, Insulet made no attempt to purchase it or to obtain one directly from EOFlow, and took no action against potential trade secret misappropriation. Appx2317; Appx1751; Appx2272; Appx2079.

In May 2021, Insulet and EOFlow renewed their discussions on potential collaboration. Malave shared with Insulet EOFlow’s 2021 Investor Relations presentation showing the Insulet and EOFlow patches side-by-side, noting their similar dimensions, revealing EOPatch 2’s internal components, contrasting certain elements such as Insulet’s SMA wire mechanism with EOFlow’s electro-osmotic actuator, and identifying EOPatch 2’s internal designs—which plainly showed Insulet the design similarities between these patches:



Appx1024; Appx1028. Within three years of the ADA conference, Insulet had these materials in hand—but only now claims the EOPatch 2’s internal components were designed using its “trade secrets.”

EOFlow’s 2021 presentation further characterized EOPatch 2 as the “sole competitor to Insulet . . . the monopolistic market leader,” Appx1021; disclosed EOFlow’s global marketing plans and distribution agreements; recounted EOPatch 2’s competitive advantages, Appx1027–30; and provided R&D and commercialization timelines, Appx1039. Insulet still took no steps whatsoever to protect any purported trade secrets. No cease-and-desist to EOFlow, not even a note to its ex-employees reminding them of any prior obligations.

In September 2021, EOFlow posted a video to its YouTube channel showing the EOPatch 2’s internal layout and components. Appx2394. A week later, Insulet made a presentation with screenshots from EOFlow’s video, labeling EOPatch’s

internal components, including the needle mechanism, gear-driven piston, helical spring, and fill port—some or all of which Insulet later claimed as trade secrets. *Id.*

Throughout the balance of 2021 and 2022, Insulet created more internal presentations tracking EOFlow’s commercialization, collaborations, investments, and expansion. *See, e.g.*, Appx2406; Appx2428. As one example, a December 2022 internal presentation contained an “[a]nalysis” of the EOPatch 2—again confirming that Insulet remained well aware that EOFlow had developed a similar product and hired former Insulet employees. Appx2465. At the same time, Insulet employees and Insulet’s outside counsel were frequenting EOFlow’s website, dozens of times per month. Appx2468. Yet Insulet still said nothing to EOFlow.

Late in 2022 or in early 2023, Insulet obtained and tore down an EOPatch. Appx2079. Benjamin claims Insulet felt “gutted,” “numb,” and “violated” by the pictures, deeming EOPatch 2 a “copy” of Omnipod. Appx2608; Appx2080–81; Appx2090. The tear-down prompted Insulet to file a patent infringement lawsuit in Germany in only three weeks’ time. *See* Appx1480. By contrast, even after the February 2023 tear-down of the EOPatch 2—the product Insulet had deemed “strikingly similar” to its Omnipod five years earlier—Insulet did not proceed to a U.S. courthouse or raise claims anywhere about any purported “trade secrets.” Insulet instead contemplated purchasing EOFlow. *See* Appx2517.

In February 2023, industry outlets reported that Medtronic began diligence to acquire EOFlow; a public announcement followed in May. Appx1071–75; Appx1076–79; Appx1080–84. Only well after this announcement, in August 2023, did Insulet file this trade secret case demanding “emergency” relief. Appx94.

II. PROCEDURAL BACKGROUND

Insulet sued EOFlow, including for infringement of “trade secrets related to the development, design, manufacturing, production of the Omnipod,” on August 3, 2023. Appx114.

Fifteen days later, Insulet filed its “emergency” motion for a temporary restraining order and preliminary injunction to enjoin all technical communications between EOFlow and Medtronic. Appx156–51. This motion was based solely on Insulet’s trade secrets claim. *See id.*; Appx162.

On August 29, 2023, the district court temporarily restrained EOFlow from “disclosing product or manufacturing technical information related to the EOPatch or Omnipod products.” Appx1256; Appx2377. It then ordered expedited discovery even beyond what Insulet had requested, including depositions, production of thousands of technical documents, and the exchange of expert reports. ECF No. 63. During this expedited discovery period, although Insulet served no document requests whatsoever on the Individual Defendants, EOFlow of its own accord searched the Individual Defendants’ devices, found old Insulet confidential

documents retained on DiIanni's and Welsford's non-EOFlow devices, and voluntarily produced them. *See* Appx1654–55.

In its opposition to Insulet's motion for a preliminary injunction, EOFlow addressed all four factors relevant to a preliminary injunction. EOFlow argued that Insulet failed to demonstrate a likelihood of success or irreparable harm, and that both the balance of potential harms and the public interest favored denying the motion. *See* Appx1610–90.

Specifically, EOFlow argued that Insulet failed to demonstrate a likelihood of success on the merits because Insulet's DTSA claim was time-barred and because Insulet had failed to show that its numerous asserted trade secrets qualified for trade secret protection. Appx1649–54; Appx809–11. EOFlow further argued that Insulet could not rely solely upon Insulet documents found on the Individual Defendants' devices to prove misappropriation against *EOFlow*, as these documents, confidential or otherwise, do not equate to trade secrets, and Insulet failed to demonstrate that EOFlow knowingly benefitted from them. Appx1654–59. EOFlow also argued that there was no significant risk of irreparable harm because: (i) Insulet delayed filing this lawsuit for years after notice of misappropriation, (ii) EOFlow did not and could not soon sell its EOPatch product in the United States, (iii) Insulet's alleged trade secrets were stale and not in continuous use, and (iv) Insulet had adequate remedies at law. Appx1636–49.

On October 4, 2023, the district court ruled from the bench and granted Insulet’s preliminary injunction motion. Appx1–34. The district court “express[ed] no opinion about the accrual of the statute of limitations,” but nonetheless proceeded to conclude that Insulet was likely to succeed on the merits of its claim. Appx15. The district court opined that there was “strong evidence of misappropriation,” mostly because “EOFlow hired four . . . former Insulet employees,” who retained “Insulet’s confidential documents.” Appx5. The district court stated, *with no analysis*, that these “confidential documents” “fall[] within the statutory definition of trade secret.” Appx6. The statutory definition invoked by the court, however, delineates only the types of information that *may* qualify as trade secret “if” other requirements are met, and those requirements were neither established by Insulet nor addressed by the district court. 18 U.S.C. § 1839(3).

Given its (erroneous) conclusion on likelihood of success, the district court believed “less in the way of irreparable harm” was required, and that such harm to Insulet crystallized when EOFlow announced the Medtronic transaction, which “would be a source of capital for EOFlow” and increase competition for Insulet. Appx20–21. In a cursory pronouncement, the district court determined the balance of equities “favors the issuance of a preliminary injunction” based solely on the fact that “Insulet, according to the evidence, appears to have been a victim of the theft of

its trade secrets,” and opined there was “little impact one way or the other” on the public interest. Appx22.

The district court then issued a sweeping order (the “Order”) that went far beyond prohibiting the transfer of information to third parties that Insulet requested. Appx38–41. In addition, the district court enjoined EOFlow “from manufacturing, marketing, or selling any product that was designed, developed, or manufactured, in whole or in part, using or relying on the Trade Secrets of Insulet.” Appx38. The Order then equated purported “Confidential Information” with Trade Secrets. The district court held that “any and all Confidential Information of Insulet, as defined in this Order, (a) that was copied, downloaded, removed, or otherwise taken from Insulet by Luis J. Malave, Steven DiIanni, Ian Welsford, or Robert Strand, or any other present or former employee or agent of Insulet, or (b) any information that contains, derives from, or incorporates such Confidential Information” was now a Trade Secret. Appx39. Rather than provide a bounded or reasonably particularized definition of the alleged Trade Secrets, the Order also proceeded to expansively include as “Confidential Information”—and thus “Trade Secret”—“(a) any and all information or materials that were marked ‘confidential’ by Insulet and (b) any and all CAD files, drawings, or specifications created by Insulet, whether or not they were marked ‘confidential.’” *Id.*

Defendants sought reconsideration, arguing that the Order would not only extinguish EOFlow as an existing business well before any trial could occur, but would also deprive patients, and in particular children, of their existing diabetes treatment. ECF No. 130. After a hearing, and over Insulet’s objection, the district court amended the preliminary injunction and added limited carveouts for certain ex-U.S. patients and clinical trials, but otherwise left the Order intact. Appx40–41. This appeal timely followed. Appx7873.

SUMMARY OF THE ARGUMENT

The district court’s decision granting Insulet a preliminary injunction was marred by legal error and should be reversed.

First, the district court erred in finding a likelihood of success on the merits while failing to address EOFlow’s dispositive statute of limitations defense. The DTSA’s statute of limitations is three years after a plaintiff is on inquiry notice. Here, Insulet indisputably learned that EOFlow had developed a “strikingly similar” product and hired several of its key employees or consultants five years before this suit was filed. That should have been the end of the matter: by definition, a time-barred claim cannot succeed on the merits. Instead of stopping there, the district court skipped this analysis entirely, explicitly *disavowed* the required analysis, and then proceeded to make additional, downstream legal errors. For example, the district court (a) wrongly assumed that all materials marked “confidential” (along

with other, unmarked materials) automatically constituted trade secrets; and (b) wrongly held that a product may be claimed as a trade secret even though it can be reverse engineered. These conclusions and others run headlong into decades of black-letter trade secrets law, which should have foreclosed any finding that Insulet would likely succeed on the merits.

Second, the district court erred in finding that Insulet faces a significant risk of irreparable harm. Insulet's prolonged delay precludes a finding of such harm, particularly where (a) the information at issue was, by Insulet's account, misappropriated years ago; (b) the purported threat is merely EOFlow's potential acquisition by Medtronic, whose diligence Insulet knew about for months before filing suit; and (c) the competitive harm Insulet claimed could easily be compensated with damages, rather than extraordinary injunctive relief.

Third, the district court failed to meaningfully weigh the balance of harms or the injury to the public interest. Instead, the district court issued a sweeping order that imperils EOFlow's existence and restricts patient access to essential treatments.

When the district court's legal errors are corrected, the record does not support a finding that Insulet would likely succeed on its claim that its purported trade secrets were protectible or misappropriated; that the district court's extraordinary remedy was justified by a meaningful threat of irreparable harm; or that such an order balances harm, fosters competition, or protects the public interest. The ruling should

be reversed.

STANDARD OF REVIEW

This Court will “review a preliminary injunction order under the law of the regional circuit”—here, the First Circuit. *SoClean, Inc. v. Sunset Healthcare Sols., Inc.*, 52 F.4th 1363, 1367 (Fed. Cir. 2022). While the First Circuit reviews preliminary-injunction decisions for abuse of discretion and questions of fact for clear error, “it reviews underlying questions of law de novo.” *Id.*

“[A]buse of discretion occurs . . . when a material factor deserving significant weight is ignored, when an improper factor is relied upon, or when all proper and no improper factors are assessed, but the court makes a serious mistake in weighing them.” *I.P. Lund Trading ApS v. Kohler Co.*, 163 F.3d 27, 33 (1st Cir. 1998) (quotation omitted). A district court may not reject a defense against a preliminary injunction motion *sub silentio*. See *Nutrition 21 v. United States*, 930 F.2d 867, 870–72 (Fed. Cir. 1991) (vacating preliminary injunction where the district court failed to make any findings on defense). Here, where the district court made several legal errors and repeatedly ignored material factors, the injunction should be reversed under any standard.

A preliminary injunction is “an extraordinary remedy that may only be awarded upon a clear showing that the plaintiff is entitled to such relief.” *Winter v. NRDC, Inc.*, 555 U.S. 7, 22 (2008) (citing *Mazurek v. Armstrong*, 520 U.S. 968, 972

(1997) (per curiam)). As the moving party, “the burden is on [the plaintiff] to establish it is entitled to this extraordinary relief.” *Momenta Pharms., Inc. v. Amphastar Pharms., Inc.*, 686 F.3d 1348, 1352 (Fed. Cir. 2012). This requires the claimant to demonstrate all of the following: “(1) the plaintiff has a likelihood of success on the merits of his claim; (2) the plaintiff does not have an adequate remedy at law such that it will suffer irreparable harm without the injunction; (3) this harm is greater than the injury the defendant will suffer if the injunction is granted; and (4) the injunction will not harm the public interest.” *Concrete Mach. Co. v. Classic Lawn Ornaments, Inc.*, 843 F.2d 600, 611 (1st Cir. 1988).

ARGUMENT

I. THE DISTRICT COURT ERRED IN ANALYZING SUCCESS ON THE MERITS BECAUSE IT IGNORED AND MISAPPLIED TRADE SECRET LAW.

DTSA claims must be asserted within three years after any misappropriation “is discovered or by the exercise of reasonable diligence should have been discovered,” which should bar Insulet’s claim. 18 U.S.C. § 1836(d). But here, the district court failed to analyze the statute of limitations altogether. Indeed, the district court’s oral order led with: “I express no opinion about the accrual of the statute of limitations.” Appx15. This error is one of several, but standing alone is grounds for reversal, as the error infected and undermined any analysis as to whether Insulet’s untimely claim was somehow likely to succeed.

Even if Insulet’s suit had been timely filed, “[t]o establish a claim for misappropriation of trade secrets under [the DTSA], a plaintiff must show that: (1) the information at issue qualifies as a trade secret, (2) it took reasonable steps to preserve the secrecy of the information, and (3) the defendant used improper means, in breach of a confidential relationship, to acquire and use the trade secret.” *KPM Analytics N. Am. Corp. v. Blue Sun Sci., LLC*, 2021 WL 2982866, at *12 (D. Mass. July 15, 2021) (quotations omitted). The district court, hedging that it had “a great deal of information coming at [it] very quickly,” Appx4, erred on each element of this substantive analysis. Among other things, the court did not (a) meaningfully analyze whether Insulet’s purported confidential information was a protectible trade secret; (b) examine whether Insulet took reasonable measures to guard the secrecy of the information at issue, even after it learned of potential misappropriation; or (c) follow the law holding that information that can be reverse engineered is “readily ascertainable,” and thus not trade secret. 18 U.S.C. § 1839(3).

A. Reversal Is Warranted Because Insulet’s Claim Is Untimely, and the District Court Failed to Analyze the Statute of Limitations.

Insulet’s claim should be barred under the DTSA’s statute of limitations, which requires that claims be asserted within three years after any misappropriation “is discovered *or by the exercise of reasonable diligence should have been discovered.*” 18 U.S.C. § 1836(d) (emphasis added). As the district court recognized, “a cause of action accrues when a party is put on inquiry notice of a

possible claim.” Appx13; *see, e.g., Hardwire, LLC v. Freyssinet Int’l Et Cie*, 2023 WL 1819321, at *3 (E.D.N.Y. Feb. 8, 2023) (the DTSA “incorporate[s] the concept of inquiry notice”); *see also Warren Freeddenfeld Assocs., Inc. v. McTigue*, 531 F.3d 38, 44 (1st Cir. 2008) (defining inquiry notice as when “a reasonably diligent person, similarly situated, would have made such a discovery,” and explaining that “a plaintiff can be charged with inquiry notice, sufficient to start the limitations clock, once he possesses information fairly suggesting some reason to investigate whether he may have suffered an injury” (citations omitted)).

Here, as noted, the district court explicitly declined to analyze whether that statute of limitations had run, summarily stating: “I express no opinion about the accrual of the statute of limitations.” Appx15. This error, standing alone, is grounds for reversing the injunction order because “time-barred claims necessarily have no chance of success.” *Winnett*, 609 F.3d at 408; *accord, e.g., Gonzalez v. Real Time Resols., Inc.*, 2019 WL 7596277, at *7 n.4 (D.N.H. Aug. 29, 2019) (“Plaintiffs have no likelihood of success on the merits of a claim that is time barred.”); *Skarzynski v. U.S. Bank NA*, 2018 WL 2247240, at *1 (D. Mass. May 16, 2018) (“[T]he court is compelled to find Plaintiffs have failed to demonstrate a substantial likelihood of success of the merits of their underlying claims because their allegations relate to actions occurring well outside the statute of limitations period.”).

Had the district court examined the timeliness issue, this motion would have been easy to decide: Insulet’s claim is barred by the DTSA’s three-year limitations period because Insulet was on inquiry notice of the alleged misappropriation *five years* before filing suit. In 2018, Insulet’s head of R&D, Eric Benjamin, saw the EOPatch device at the ADA trade show and concluded the EOPatch “bore a stunning resemblance to the Omnipod.” Appx216; Appx2062; *see also* Appx97 (alleging that “in 2018, EOFlow started advertising its . . . strikingly similar” product). This 2018 trade-show viewing gave rise to textbook inquiry notice under the law, and sparked Insulet’s “technical curiosity,” such that Insulet “constantly watched” EOFlow’s operations and press releases. Appx217.

Accordingly, in 2019, Insulet reached out to EOFlow and obtained an “overview” of the EOPatch 2 product, learned that EOFlow had obtained regulatory approval in Korea, and learned that EOFlow had entered a distribution agreement to “commercialize the Insulin Patch Pump product.” Appx1065–68; Appx1123–24; Appx1229–31. In 2021, Insulet’s knowledge deepened: Insulet continued these discussions with EOFlow, conducted its own internal review of the EOPatch, *see* Appx1628; Appx2272; Appx2290; Appx2307, and watched EOFlow commercially launch and begin selling its EOPatch in Korea, *see* Appx1747; Appx1751; Appx2317; Appx2272. Yet only in 2023—long after the limitations period expired—did Insulet finally examine EOFlow’s product and file this action.

Appx98.

Courts in the First Circuit and across the country have consistently held that seeing a potentially infringing product at a trade show—as Insulet did more than five years ago—provides inquiry notice and starts the clock on a DTSA claim. For example, in *AnywhereCommerce, Inc. v. Ingenico Inc.*, the court held a trade secret claim untimely because the plaintiff, like Insulet, “saw the [defendant’s] product at the [] trade show” and recognized it as “very similar” more than three years before filing suit. 2023 WL 2694043, at *12 (D. Mass. Mar. 29, 2023); *see also, e.g., CMI Roadbuilding, Inc. v. Iowa Parts, Inc.*, 920 F.3d 560, 565 (8th Cir. 2019) (affirming trade secret claim was time-barred because “exhibits at an [industry] trade show” put plaintiff “continuously on notice” with “a duty to investigate, regardless of [its] exact knowledge”); *MGA Ent., Inc. v. Mattel, Inc.*, 41 Cal. App. 5th 554, 563–64 (2019) (holding trade secret claim untimely because an industry event provided inquiry notice, and a party “cannot don blinders to avoid the accrual of the statute of limitation”); *cf. Knights Armament Co. v. Optical Sys. Tech., Inc.*, 654 F.3d 1179, 1184 (11th Cir. 2011) (affirming trade secret claim time-barred where even the plaintiff admitted the statute of limitations started as soon as it “first viewed [the] competing device at a trade show”). As these courts have recognized, seeing a “very similar product” at a trade show, as Insulet did here, triggers inquiry notice and starts the clock on the DTSA limitations period. *AnywhereCommerce*, 2023 WL 2694043,

at *12.

Moreover, such claims accrue “[r]egardless of when” in the future a defendant’s product comes “on the market.” *Id.*; *see, e.g., Epstein v. C.R. Bard, Inc.*, 460 F.3d 183, 188 (1st Cir. 2006) (affirming dismissal of trade secret claim under Massachusetts law because “[c]ritically, knowledge of ‘every fact necessary to prevail on the claim’ is not required to put the plaintiff on inquiry notice and trigger the accrual period”); *CMI Roadbuilding*, 920 F.3d at 565–66 (affirming dismissal of DTSA claim on statute of limitations grounds because plaintiff “was on inquiry notice that a problem with possible misappropriation of its trade secrets might exist well before” filing suit); *Zirvi v. Flatley*, 838 F. App’x 582, 586 (2d Cir. 2020) (summary order) (affirming dismissal of time-barred DTSA claim because the “circumstances surely put a ‘person of ordinary intelligence’ on at least inquiry notice”).

Since the 2018 trade show viewing, Insulet “reasonably knew” EoFlow was developing a similar product (and had hired ex-Insulet personnel) “such that [Insulet] was on notice by then of the potential claim.” *AnywhereCommerce*, 2023 WL 2694043, at *12 (holding DTSA claim time-barred). Insulet’s failure to timely file suit within a three-year period dooms its DTSA claim and mandates reversal.

B. The District Court Erred in Concluding That the Information at Issue Qualified for Trade Secret Protection.

Even if Insulet’s suit had been timely filed, which it was not, the district

court's likelihood-of-success determination still could not stand because the district court erroneously applied trade secret protection when essential trade secret qualifications were not even addressed, much less established.

1. The District Court Erred by Failing to Analyze Whether Insulet Had Identified Actual Trade Secrets

Trade secret claims cannot succeed merely by pointing to categories of information that meet the definition of the *types* of information that can qualify for trade secret protection. *See, e.g., Imax Corp. v. Cinema Techs., Inc.*, 152 F.3d 1161, 1167 (9th Cir. 1998) (holding insufficient trade secret identification that “does not clearly refer to tangible trade secret material. Rather, it refers to [a system] which *potentially* qualifies for trade secret protection.”). That is because trade secrets must be identified “with specificity” in a way that “separate[s] the purported trade secrets from the other information . . . [that was] known to the trade.” *TLS Mgmt. & Mktg. Servs., LLC v. Rodríguez-Toledo*, 966 F.3d 46, 54 (1st Cir. 2020); *see also, e.g., Neural Magic, Inc. v. Meta Platforms, Inc.*, 2023 WL 2383172, at *14 (D. Mass. Mar. 6, 2023) (collecting cases requiring claimants to “define [the] trade secrets with clarity . . . and to distinguish what is protectable from that which is not” (quotations omitted)); *Zirvi v. Flatley*, 433 F. Supp. 3d 448, 465 (S.D.N.Y. 2020) (rejecting “allegations [that] resemble broad categories of information and are vague, which, by itself, constitutes a reason to dismiss the claims” (cleaned up)), *aff’d*, 838 F. App’x 582 (2d Cir. 2020).

Rather than analyze whether the specific, asserted trade secrets qualified for protection, the district court erroneously concluded that some Insulet “information falls within the statutory definition of trade secret” and expressly refused even to find the “number and contours of the trade secrets at issue.” Appx6. That is insufficient as a matter of law. While the definition of what *can qualify* as a trade secret is extraordinarily capacious, *see* 18 U.S.C. § 1839(3), it is merely an outer boundary of what *can be* a trade secret. It is not the case that “all forms and types of financial, business, scientific, technical, economic, or engineering information” *are* trade secrets, *id.*, and invoking this definition is no substitute for evaluating whether the information at issue is indeed protectible as a trade secret. As the DTSA itself explicitly provides, such materials may qualify as trade secrets only “*if*” statutory criteria are satisfied. *Id.* (emphasis added). The district court never performed this essential analysis, which alone is reversible error. *See I.P. Lund Trading ApS*, 163 F.3d at 33 (holding that “a preliminary injunction . . . decision must be supported by adequate findings of fact and conclusions of law, which compels reversal when, *inter alia*, “a material factor deserving significant weight is ignored . . . or when . . . the court makes a serious mistake in weighing them” (quotations omitted)).

Instead, the district court purported to redefine the term “trade secret” in a sweeping, indefensible manner. In entering the preliminary injunction, the court

defined “Confidential Information” as “(a) any and all information or materials that were *marked* ‘confidential’ by Insulet and (b) any and all CAD files, drawing, or specifications created by Insulet, *whether or not they were marked ‘confidential.’*” Appx35 (emphasis added). The court went on to define “Trade Secrets” as “any and all Confidential Information of Insulet” retained by any “present or former employee or agent of Insulet,” or “any information that contains, derives from, or incorporates such Confidential Information.” *Id.*

In other words, while deciding Insulet had a likelihood of success on a DTSA claim, the court did not require Insulet even to establish what actually constitutes a “Trade Secret” under the DTSA. This legal error is grounds for reversal for two primary reasons.

First, the district court improperly conflated “confidential” information with trade secrets. “[T]he mere fact that information is pertinent to someone’s trade or business and that it may also be ‘confidential,’ or ‘secret,’ does not mean it constitutes a ‘trade secret’ within the specific definitions of the . . . DTSA.” *Welter v. Med. Pro. Mut. Ins. Co.*, 2023 WL 2988627, at *15 (D. Mass. Feb. 23, 2023) (dismissing DTSA claim). The district court’s order erases this well-established distinction and holds that any information marked “confidential” that is held by any current or former Insulet employee, plus a set of documents with no markings, plus any information derived from such information, is deemed a protectible trade secret.

In effect, the district court converted a claim for breach of a confidentiality agreement (which Insulet did not bring) into one for misappropriation of trade secrets.

That was error: trade secret claims are *not* commensurate with claims that a party breached a confidentiality agreement. *See, e.g., Dynamics Rsch. Corp. v. Analytic Scis. Corp.*, 400 N.E.2d 1274, 1288 (Mass. App. Ct. 1980) (explaining that a confidentiality agreement “cannot make secret that which is not secret, and it remains for the court to determine whether an alleged trade secret is in fact such”); *Arconic Corp. v. Novelis Inc.*, 2021 WL 4479484, at *2 (W.D. Pa. Sept. 30, 2021) (“[C]onfidential information claims were different, both substantively and procedurally, than trade secret claims [because] the substantive law governing confidential information claims is less demanding.” (quotations omitted)). Trade secrets comprise a specifically defined subset of confidential information that meet specific statutory requirements. The court’s order labeling all “confidential” information as trade secret was wrong as a matter of law.

Second and relatedly, the district court impermissibly construed Insulet’s trade secrets to encompass virtually all aspects of its product. Assertions “that all information in or about [a product] is a trade secret,” are “both too vague and too inclusive.” *IDX Sys. Corp. v. Epic Sys. Corp.*, 285 F.3d 581, 583 (7th Cir. 2002); *see also Beane v. Beane*, 856 F. Supp. 2d 280, 305 (D. Mass. 2012) (“Needless to

say, [trade secret] protections . . . are considerably narrower[.]”). Thus, courts routinely reject such efforts to “categorize [as trade secret] every piece of information or know-how that could potentially have value to the company.” *Freeman Inv. Mgmt. Co. v. Frank Russell Co.*, 2016 WL 5719819, at *11 (S.D. Cal. Sept. 30, 2016), *aff’d*, 729 F. App’x 590 (9th Cir. 2018). Insulet, however, pointed only to the product’s entire manufacturing process as its commercial advantage, and could not identify any specific secret that provided “independent economic value” as a result of its secrecy. *Teradata Corp. v. SAP SE*, 2023 WL 4882885, at *10 (Fed. Cir. Aug. 1, 2023) (unpublished) (quoting 18 U.S.C. § 1839(3)); *Synopsys, Inc. v. Risk Based Sec., Inc.*, 70 F.4th 759, 771–72 (4th Cir. 2023) (“Permitting evidence of the value of the whole entity to substitute as value of a *particular* component part (the trade secrets) would defeat the obligation of proving that the alleged trade secrets themselves have independent economic value.” (emphasis added)); *see also* Appx2047; Appx2088; Appx2093 (Insulet’s declarant testifying he “can’t help” to identify “which of the[] trade secrets . . . gives Insulet the ability to manufacture the product at scale”); Appx2125 (“[A]ll of the[]” steps in the assembly process were the source of “Insulet’s competitive advantage”).

The district court’s order went even further than claiming the entire product was secret, and purported to define as an Insulet trade secret every CAD file, drawing, or specification *and* any information “derived” in any way from those

sources. Appx39. Materials such as CAD drawings and specifications, however, have repeatedly been held *not* to qualify as trade secrets for commercially available products because they are mere blueprints for features that become “readily ascertainable.” 18 U.S.C. § 1839(3)(B); *see, e.g., Broad-Ocean Techs., LLC v. Lei*, 2023 WL 145001, at *7 (E.D. Mich. Jan. 9, 2023) (rejecting the “circular argument that its computer-aided design files are secret” because a plaintiff must “explain with greater specificity” which information is secret); *Vita Int’l, Inc. v. Foro Energy, Inc.*, 2022 WL 350195, at *16–17 (S.D. Tex. Jan. 4, 2022) (holding that plaintiff’s “conceptual drawing”—an AutoCAD file depicting a mechanical part—was not a trade secret because “all critical features of the conceptual drawings . . . would inevitably have been visually observable”).

To the extent the district court assumed the combination of information was protectible as a trade secret “soup,” Appx30, the record does not show—and the district court did not say—*what* combination of information was allegedly a trade secret. *See TLS Mgmt. & Mktg. Servs.*, 966 F.3d at 54 (“[S]imply to assert [that] a trade secret resides in some combination of otherwise known data is not sufficient . . . the combination itself must be delineated with some particularity[.]” (quoting *Montevideo Tech., Inc. v. Eaton Aerospace, LLC*, 491 F.3d 350, 354 (8th Cir. 2007))).

And, if the district court meant to say that Insulet’s invocation of an

undifferentiated mass of information shifted the burden to defendants, that too was legal error. *Compare* Appx30 (“[I]t becomes a soup where it’s hard to, you know, break out the individual agreements, and it’s all put together, *and the case law is that that wrongdoer, you know, has to demonstrate at some point, you know, why what he did was, in fact, not wrongful conduct*” (emphasis added)), with, e.g., *Green Earth Energy Photovoltaic Corp. v. KeyCorp*, 2020 WL 1816379, at *8 (D. Mass. Jan. 10, 2020) (“[W]ith all elements for a preliminary injunction, the burden is on Plaintiffs”); *Am. Inst. for Foreign Study, Inc. v. Fernandez-Jimenez*, 468 F. Supp. 3d 414, 426 (D. Mass. 2020) (“An injunction is never awarded as of right and it is the burden of the moving party to establish that all four preliminary injunction factors are met”), *aff’d*, 6 F.4th 120 (1st Cir. 2021). It has long been established that where plaintiffs come “in equity for an injunction, [] the burden is on them to prove *all* the material allegations.” *United States v. Hooe*, 7 U.S. (3 Cranch) 73, 88 (1805).

The district court had no grounds to deviate from this law merely because neither the court nor Insulet could “break out”—that is, identify with particularity—any actual trade secrets. Appx30.

2. The Record Does Not Demonstrate That Insulet Took the Requisite “Reasonable Measures” to Protect the Asserted Trade Secrets

Information cannot qualify for trade secret status unless “the owner thereof has taken reasonable measures to keep [such information] secret.” *Teradata*, 2023

WL 4882885, at *10 (quoting 18 U.S.C. § 1839(3)); *see also CVD, Inc. v. Raytheon Co.*, 769 F.2d 842, 851 (1st Cir. 1985) (“[T]o be protected by law, a trade secret must be kept in secret.”). The district court erred in analyzing whether Insulet took these “reasonable measures” in two critical respects.

First, the district court ignored the rule that failure to take actions *after* discovering potential misappropriation undermines a party’s claim that it took “reasonable measures” to guard the alleged secrets. “[A]ctions taken after the alleged misappropriation are relevant to whether information can be properly categorized as a trade secret.” *Neural Magic*, 2023 WL 2383172, at *22 (citing *J. T. Healy & Son, Inc. v. James A. Murphy & Son, Inc.*, 260 N.E.2d 723, 730–31 (Mass. 1970) (holding that if a party “wishes to have . . . exclusive use” of information, it “must exercise eternal vigilance”))). Yet here, the district court addressed *only* steps taken before the alleged misappropriation and performed no analysis whatsoever of whether Insulet took reasonable measures after it saw EOFlow’s strikingly similar product promoted by its ex-employee in 2018, and received presentations showing the EOPatch 2’s inner workings, regulatory approvals, commercialization plans, and distribution agreements in 2019, 2020, and 2021. The district court even suggested that trade secret claims “are different” from trademark infringement claims, suggesting that “[i]f you become aware that your company’s name . . . is being used, you’re required to take action immediately,”

including by sending “cease and desist letters,” but that no such diligence is needed to protect trade secrets. Appx13–14.

Yet that is precisely what courts require, at a minimum, of a trade secret claimant. For example, the Fifth Circuit recently affirmed the dismissal of a DTSA claim because the plaintiff “waited two years without sending any cease-and-desist letter or requesting any preliminary injunctive relief.” *Pie Dev., LLC v. Pie Ins. Holdings, Inc.*, 2023 WL 2707184, at *3 (5th Cir. Mar. 30, 2023) (per curiam) (unpublished). Other courts have imposed the same requirement on parties asserting trade secret claims. *See, e.g., HiRel Connectors, Inc. v. United States*, 2005 WL 4958547, at *4–5 (C.D. Cal. Jan. 4, 2005) (holding that trade secret protection is lost “despite many years of diligent efforts to maintain confidentiality if, through voluntary action or inadvertence, [the owner] ceases those efforts” for “months or years,” allowing “competitors to locate and use these secrets”); *iAlamar Biosciences, Inc. v. Difco Lab’ys, Inc.*, 1995 WL 912345, at *6 (E.D. Cal. Oct. 13, 1995) (plaintiff’s failure to “even approach and warn” the defendant promptly when suspicions arose “establishes that [party] did not take reasonable steps to protect its trade secrets”). The district court failed to perform this essential inquiry into the “reasonable measures” required to assert, much less succeed on, a DTSA claim.

Second, the district court erred in holding that “at least as to some substantial set of information, Insulet took reasonable steps to protect the information.

Documents were marked confidential, employees were required to sign nondisclosure or confidentiality agreements, systems were password protected, and the like.” Appx5–6. Finding a likelihood of success based on these conclusions is legal error.

To start, finding that Insulet took measures to protect some unidentified “set of information” is *not* the same as finding that Insulet took “reasonable measures” to protect the specific, asserted trade secrets, as the DTSA requires. 18 U.S.C. § 1839(3)(A). And, of course, some documents the district court deemed trade secret were *not* marked confidential. Appx39 (holding that the “Trade Secrets” included “any and all CAD files, drawings, or specifications . . . whether or not they were marked ‘confidential.’”). Moreover, merely imposing a nondisclosure agreement on an employee—as virtually all companies do today—does not, as the district court believed, render information a protectible trade secret. *See, e.g., Dynamics Rsch.*, 400 N.E.2d at 1287–90 (affirming that “inadequate precautions did not warrant relief . . . though the defendant had signed an agreement not to disclose trade secrets” because such an agreement “can only affirm the intent of the parties to be bound by the [] law of trade secrets . . . [that] does not aid the plaintiff”).

Plus, the record lays bare how little Insulet did to guard the secrecy of its information even before learning of potential misappropriation. For example, there is no dispute that DiIanni was allowed to maintain and use Insulet “confidential”

materials on his personal laptop or that Insulet failed to even ask him to return or destroy those documents when he left the company. *See* Appx1915. As in *Abrasic 90 v. Weldcote Metals*, Insulet did not ask the departing employees “what information they possessed, admonish[] them about the confidentiality of certain information, or demand[] that they return any specific information.” 364 F. Supp. 3d 888, 900 (N.D. Ill. 2019). Nor did testimony support the district court’s statement that relevant systems were password protected. *See* Appx2085–86 (Insulet employee admitting he did “not have personal knowledge” of “any security measures that Insulet had in place” during the ex-employees’ tenure); Appx2139 (Insulet employee testifying that, on the subject of measures used to “control access to [Insulet’s] drawings,” he could not “speak to [the] IT infrastructure” or who could access the materials, except that “we have to have log-ins and stuff like that”). Insulet’s lack of signed contracts, its willingness to let the employees use the information at issue on personal devices without ever requesting their return, and its failure to do anything after seeing a similar product promoted by its own ex-employees, are all relevant factors the court failed to consider in analyzing the required “reasonable measures.”

Each of these mistakes in the analysis of reasonable measures, standing alone, constitutes reversible error. Without a demonstration that Insulet took “reasonable measures” to protect the specific information at issue both before and after the

alleged misappropriation, there are no established trade secrets, and no trade secret claim that is likely to succeed. 18 U.S.C. § 1839.

3. The District Court Erred in Holding That Information That May Be Reverse Engineered Constitutes a Trade Secret

Under the DTSA, information cannot qualify for trade secret protection if it is “readily ascertainable through proper means,” including “reverse engineering.” 18 U.S.C. § 1839(3)(B), 6(B). The Supreme Court has long recognized that the “public at large remain[s] free to discover and exploit the trade secret through reverse engineering of products in the public domain or by independent creation.” *Bonito Boats, Inc. v. Thunder Craft Boats, Inc.*, 489 U.S. 141, 155 (1989); *see also Kewanee Oil Co. v. Bicron Corp.*, 416 U.S. 470, 476 (1974) (“[T]rade secret law [] does not offer protection against discovery by . . . reverse engineering, that is by starting with the known product and working backward to divine the process which aided in its development or manufacture.”).

Here, there is no dispute that the information claimed as trade secrets could be reverse engineered. Insulet’s own witness, for example, testified that “yes,” it is “possible to deconstruct an Omnipod and eventually build a prototype copy of the Omnipod.” Appx2087. Insulet also admitted to the district court that “of course” the Omnipod “can be broken down and to some extent reverse engineered.” Appx8.

In finding a likelihood of success, the district court held that “*the mere possibility that something could be reverse engineered without more is not enough to defeat a trade secret claim.*” Appx8–9 (emphasis added).

That conclusion contradicts the DTSA itself and a mountain of case law holding that information that *can be* reverse engineered is not a trade secret. *See, e.g., Bonito Boats*, 489 U.S. at 155; *Kewanee Oil*, 416 U.S. at 476; *Alpha Pro Tech, Inc. v. VWR Int’l, LLC*, 2017 WL 3671264, at *8 (E.D. Pa. Aug. 23, 2017) (explaining that a “product is not entitled to trade secret protection . . . if it is susceptible to reverse engineering, regardless of whether [defendants] in fact went through such an exercise” (quotation omitted)); *Walker Mfg., Inc. v. Hoffmann, Inc.*, 261 F. Supp. 2d 1054, 1081 (N.D. Iowa 2003) (“[Defendant] may properly assert that certain matters are not ‘trade secrets,’ if they can be discovered by ‘reverse engineering,’ even if [Defendant] does not assert, as a defense to a claim of misappropriation of trade secrets, that it in fact obtained those matters by reverse engineering.”); *see also United Steelworkers of Am., AFL-CIO-CLC v. Auchter*, 763 F.2d 728, 740 (3d Cir. 1985) (information “determinable by reverse engineering . . . has not traditionally been afforded trade secret protection” under *Kewanee* and applicable state law). These common law decisions track the language of the DTSA, which does not ask whether information was readily “ascertained

through proper means,” as the district court held, but rather is “ascertainable” through such means, like reverse engineering. 18 U.S.C. § 1839(3)(B), (6)(B).

In sum, the district court’s agreement with Insulet’s admissions and EOFlow’s position that (at least) the Omnipod’s physical features “could be reverse engineered,” Appx8–9, should have ended the matter. The information the Omnipod embodies does not qualify for trade secret protection, and the district court’s contrary conclusion is legal error.²

4. The District Court Failed to Consider Extensive Evidence That Insulet’s Purported Trade Secrets Are Public Knowledge or Generally Known in the Industry.

“A plaintiff seeking relief for misappropriation of trade secrets must identify the trade secrets and carry the burden of showing that they exist,” including by “separat[ing]” the trade secret “from matters of general knowledge in the trade or of special knowledge of those persons . . . skilled in the trade.” *Imax*, 152 F.3d at 1164–

² Even under the district court’s incorrect view that product features are entitled to trade secret protection unless they were “actually reverse engineered,” Appx9, the evidence established that EOFlow both performed its own extensive development efforts and reverse engineered the Omnipod. EOFlow’s CEO testified that his team of engineers performed this reverse engineering “at least since 2014 every year.” Appx1733–34 (testifying that EOFlow “reverse engineered” and “studied” the Omnipod); *see also* Appx1995 (2015 teardown photo); Appx1999 (2016 teardown photo); Appx2001 (2016 teardown photo); Appx2013 (2018 teardown photo); Appx4869 (2018 teardown photo). This reverse engineering allowed EOFlow to ascertain precisely the Omnipod features that Insulet now claims as its trade secrets. *See, e.g.*, Appx4667–98; Appx4708–32; Appx4787–4801; Appx4842–52; Appx4878–4902.

65 (quotations omitted). Thus, “[m]atters of public knowledge or of general knowledge in an industry cannot be appropriated by one as his secret.” *Sutra, Inc. v. Iceland Exp., ehf*, 2008 WL 2705580, at *3 (D. Mass. July 10, 2008). Accordingly, there is no trade secret protection for information that has been disclosed in “published papers,” “a film,” or “photographs.” *CVD*, 769 F.2d at 852. Similarly, “disclosure of a trade secret in a patent places the information comprising the secret into the public domain,” such that “the trade secret is extinguished.” *Ultimax Cement Mfg. Corp. v. CTS Cement Mfg. Corp.*, 587 F.3d 1339, 1355 (Fed. Cir. 2009); *see also Blake v. Pro. Coin Grading Serv.*, 898 F. Supp. 2d 365, 380 (D. Mass. 2012) (dismissing attempt to claim trade secret protection over materials disclosed in publication and patent applications because information “readily known or knowable to the interest of the public cannot . . . be made confidential simply by slapping it with a restrictive label.”).

EOFlow thoroughly addressed this issue. Across dozens of exhibits and voluminous briefing and expert declarations, EOFlow provided ample evidence that Insulet’s asserted trade secrets were disclosed in published papers, photographs, videos, and patents. *See, e.g.*, Appx838–41; Appx1661–77; Appx1367–1451.

This evidence established that the purported trade secret information Insulet identified is indeed public knowledge or generally known in the industry. At the very least, EOFlow’s experts provided “conflicting evidence” as compared to

Insulet's on this issue, which was enough to defeat Insulet's motion. *See, e.g., McDonough v. Trs. of Univ. Sys. of New Hampshire*, 704 F.2d 780, 783–84 (1st Cir. 1983) (affirming denial of preliminary injunction because “unresolved factual disputes [were] abundant” and recognizing that “it is difficult to obtain preliminary injunctive relief in cases, like this one, that involve intensely fact-oriented disputes”); *Spencer Cos., Inc. v. Armonk Indus., Inc.*, 489 F.2d 704, 707 (1st Cir. 1973) (affirming denial of preliminary injunction in light of “major factual dispute”); *City of Lowell v. Enel N. Am., Inc.*, 705 F. Supp. 2d 116, 121 (D. Mass. 2010) (“The [plaintiff] has not demonstrated a likelihood of success on the merits because too many factual disputes and uncertainties remain.”). Where, as here, a defendant “provided substantial evidence to suggest that these concepts were widely known by those of skill in the field and that any one of them or the combination of them, were not [] proprietary trade secrets,” an injunction should not issue. *Neural Magic, Inc. v. Facebook, Inc.*, 2020 WL 13819257, at *4 (D. Mass. May 29, 2020) (denying preliminary injunction).

The district court addressed none of this evidence. The closest the district court came was an acknowledgement that “because Insulet has patents, it necessarily disclosed information in those patents or patent applications,” but went no further to determine what, if anything, remained secret. Appx9. Instead, the district court waved off the issue of prior disclosures by fiat, stating “[t]hat’s true, but that’s, of

course, not what we’re talking about here.” *Id.*

In awarding the extraordinary remedy of a preliminary injunction, the district court’s refusal to address evidence necessary to “separate the [purported] trade secrets” from other information “known to the trade” was legal error. *TLS Mgmt. & Mktg. Servs.*, 966 F.3d at 54; *see, e.g., In re Search Warrant Issued June 13, 2019*, 942 F.3d 159, 172 (4th Cir. 2019) (reversing order granting preliminary injunction where district court “failed to address [party’s] un rebutted evidence” and “ignored evidence” related to irreparable harm), *as amended* (Oct. 31, 2019); *Ezold v. Wolf, Block, Schorr & Solis-Cohen*, 983 F.2d 509, 530–32 (3d Cir. 1992) (reversing preliminary injunction due to “district court’s failure to consider” significant evidence).

This district court erred in ignoring and dismissing this key factor, which is a baseline requirement for any likelihood of success on a trade secret claim.

C. The District Court Erred in Finding Misappropriation.

To establish “misappropriation” under the DTSA, Insulet must show “disclosure or use of a trade secret of another without express or implied consent by a person who . . . at the time of disclosure or use, knew or had reason to know that the knowledge of the trade secret was . . . acquired under circumstances giving rise to a duty to maintain the secrecy of the trade secret or limit the use of the trade secret.” *Allscripts Healthcare, LLC v. DR/Decision Res., LLC*, 386 F. Supp. 3d 89,

94 (D. Mass 2019) (quoting 18 U.S.C. § 1839(5)(B)); *accord Teradata*, 2023 WL 4882885, at *10. Even if Insulet had demonstrated the existence of trade secrets, the district court’s finding of misappropriation constituted legal error in at least three respects.

First, the district court erred in assuming that EOFlow’s decision to “hire or engage[] former Insulet employees” or consultants demonstrated misappropriation. Appx5; *see also, e.g.*, Appx7 (“And, again, this was done by the former Insulet employees[.]”); Appx9 (“It appears that EOFlow itself was unable to do so before hiring Insulet’s former employees and using its documents.”). There is nothing wrong with recruiting former employees: “It is well settled that an employee’s general skill and knowledge is the type of information that he can carry away and use after termination of his employment.” *Harvard Apparatus, Inc. v. Cowen*, 130 F. Supp. 2d 161, 175 (D. Mass 2001). Indeed, “[t]he principle of allowing the employee to carry away and use his general knowledge and skill acquired during his employment ‘effectuates the public interest in labor mobility, promotes the employee’s freedom to practice a profession, and freedom of competition.’” *Id.* at 175 n.31 (quoting *CVD*, 769 F.2d at 852). The district court’s apparent belief that hiring former employees or consultants amounted to “improper means” simply has no basis in trade secrets law.

Second, the district court erred in assuming that these former employees’

mere retention of confidential documents—absent evidence that EOFlow actually knew of or relied upon them—established misappropriation. The notion that the employees retained documents and the company relied on those employees, as any company would, does not establish misappropriation by EOFlow. To the contrary, courts have long explained that, where the evidence is “just as consistent” that a company like EOFlow is an “innocent beneficiary of trade secret information” it receives from an employee or contractor, it “does not follow that [the company] knew that this is what [the employee or contractor] was doing,” and the company cannot be liable for trade secret misappropriation. *Am. Sci. & Eng’g, Inc. v. Kelly*, 69 F. Supp. 2d 227, 233–34, 239 (D. Mass. 1999) (denying preliminary injunction). That is precisely the case here—indeed, EOFlow specifically sought and received contractual assurances before engaging DiIanni that he would *not* breach any “prior” obligations to protect any “Proprietary Information.” Appx1985. The district court’s failure to determine whether EOFlow relied upon—or even knew about—the confidential documents retained by Insulet’s former employees was error. *See, e.g., Aggreko, LLC v. Koronis*, 2013 WL 6835165, at *4–5 (D. Mass. Dec. 19, 2013) (denying preliminary injunction even though “at least some of the information accessed and taken by [plaintiff’s former employee] constitutes trade secrets” because “[plaintiff] has not yet met its burden of showing it is likely that [defendants] acquired or used any of this information”); *Nova Design Techs. v. Walters*, 875 F.

Supp. 2d 458, 473-74 (E.D. Pa. 2012) (“the record contain[ed] no evidence that a corporate defendant was aware that any information it allegedly misappropriated was improperly obtained”).

Third, despite voluminous expert submissions from the parties, the district court did not even attempt to assess the numerous differences between the Insulet and EOFlow products. It is well settled that differences between a defendant’s product and a plaintiff’s may defeat a claim of misappropriation. *See, e.g., Town & Country Linen Corp. v. Ingenious Designs LLC*, 556 F. Supp. 3d 222, 283 (S.D.N.Y. 2021) (rejecting misappropriation claim where, *inter alia*, defendants’ “final product alleged to be a copy is *not* substantially similar in many respects”); *Cinebase Software, Inc. v. Media Guar. Tr., Inc.*, 1998 WL 661465, at *11 (N.D. Cal. Sept. 22, 1998) (denying preliminary injunction on the grounds that “the evidence of similarity is insufficient to establish threatened misappropriation,” in light of differences that made clear that defendant’s “planned product will not be an exact replica” of plaintiff’s); *Flotec, Inc. v. S. Rsch., Inc.*, 16 F. Supp. 2d 992, 1003 (S.D. Ind. 1998) (finding that, “where one one-thousandth of an inch is supposed to make a big difference,” a difference of 0.001 inches precludes finding of misappropriation).

EOFlow devoted dozens of exhibits and extensive briefing to explaining the clear and crucial differences between the products—all of which should defeat a

preliminary injunction finding of misappropriation. *See, e.g.*, Appx802–03; Appx1621–24; Appx1660–77. But here again the district court did not address any of this evidence—or even identify specific similarities between the products that might support a finding of misappropriation. The district court’s award of extraordinary relief absent such a finding and absent consideration of the evidence before it was error. *See supra* pp. 40–42.

* * *

Accordingly, the district court’s analysis of the likelihood of success prong was marred by reversible legal errors.

II. INSULET FAILED TO SHOW A SIGNIFICANT RISK OF IRREPARABLE HARM.

“[T]he basis for injunctive relief in the federal courts has always been irreparable injury and the inadequacy of legal remedies.” *Voice of the Arab World, Inc. v. MDTV Med. News Now, Inc.*, 645 F.3d 26, 32 (1st Cir. 2011) (quoting *Weinberger v. Romero-Barceló*, 456 U.S. 305, 312 (1982)); *see also* 11A Charles Alan Wright, Arthur R. Miller & Mary Kay Kane, *Federal Practice and Procedure* § 2948 (3d ed. 2023) (recognizing irreparable harm as “[p]erhaps the single most important prerequisite”). A plaintiff cannot satisfy its burden by showing merely *some* risk of irreparable harm; the risk must be “*significant*.” *NuVasive, Inc. v. Day*, 954 F.3d 439, 443 (1st Cir. 2020) (emphasis added).

Here, the district court failed to identify any cognizable harm that was imminent or irreparable. The harm Insulet claimed was not tied to the acquisition or use of any asserted “secrets” that had left Insulet years before, and had already been the subject of Medtronic’s publicized, extensive due diligence for many months. Instead, the alleged harm was simply that Medtronic, a larger commercial player, might, at some future date, compete for insulin patch-pump sales that, if proven wrongful, could be compensated by money damages. None of that potential harm was imminent or irreparable, and the district court erred in concluding otherwise.

A. Insulet Is Not Entitled to Emergency Relief Because It Did Not Treat the Alleged Theft of Its Trade Secrets as an Emergency.

A party’s “failure to act sooner undercuts the sense of urgency that ordinarily accompanies a motion for preliminary relief and suggests that there is, in fact, no irreparable injury.” *Voice of the Arab World, Inc.*, 645 F.3d at 35; *Charlesbank Equity Fund II v. Blinds To Go, Inc.*, 370 F.3d 151, 163 (1st Cir. 2004) (“[A party’s] cries of urgency are sharply undercut by its own rather leisurely approach to the question of preliminary injunctive relief.”). The district court ignored this standard, both diminishing and excusing Insulet’s delay. That was error.

As discussed, the record is clear that Insulet waited *over five years* to assert its trade secrets. *Supra* § I.A. Insulet lay in wait, allowing EOFlow to invest tens of millions of dollars and years of engineering work on its competitive product, and

struck only once its competitor was at its most vulnerable, on the eve of being acquired.

By 2018, Insulet had not only seen EOFlow’s “stunningly similar” product, but also knew that EOFlow had hired Insulet’s “senior executives and critical employees,” Mr. Malave and Mr. Welsford, who allegedly knew “details of every aspect of [Insulet’s] research and development efforts” and had access to “every record regarding the Omnipod product.” Appx97; Appx109–10; *see also* Appx2345 (Insulet arguing for emergency relief five years later, on the grounds that “really core to a lot of this is the hiring of former Insulet top executives. That’s Luis Malave, Steven DiIanni, Ian Welsford.”). And over the next five years, Insulet received (directly from EOFlow) materials that disclosed EOPatch’s dimensions and components, described the roles of Malave and Welsford at EOFlow, and noted EOFlow’s regulatory approvals, “commercialization,” and distribution agreements; and proclaimed EOFlow as “the sole competitor to Insulet.” Appx1021–22; Appx1024; Appx1029; Appx1039.

Yet during this half decade, Insulet failed to take even the most basic measures—it sent no cease-and-desist letter to EOFlow, nor any letter asking Malave or Welsford to return or destroy confidential information or reminding them of their continuing obligations to Insulet. Having failed for “years” to take such low-cost, standard measures, Insulet’s sudden claim of urgency rings hollow. Appx2580.

The district court stated that “the lawsuit [could] have been filed more quickly,” Appx20, but viewed that delay as “not so undue in my opinion as to completely undercut the sense of urgency,” Appx22. The law stands otherwise: using *any* of the plausible dates from which a court can measure delay leads to the same conclusion—Insulet delayed too long to claim irreparable harm. That is true whether the delay is measured from:

- The 2018 date of inquiry notice, *see* Appx2104; Appx2038–39; Appx1750; Appx1752; Appx1059–61;
- Insulet’s receipt in 2019 of EOFlow’s “overview,” Appx1065–68;
- Insulet’s March 2021 internal review of EOFlow (when even the district court opined “events really begin”), Appx2272; Appx2290; Appx2307;
- The 2021 Investor Relations presentation Insulet received from EOFlow, Appx1010;
- The December 2022 Insulet documents demonstrating Insulet’s suspicion of copying, Appx2465;
- The February 2023 tear-down of the product, Appx2079; or
- The May 2023 public confirmation of the Medtronic acquisition, Appx1071–75.

All of these events preceded Insulet’s filing by months, if not years.

Courts have routinely held that such delays—often far shorter than Insulet’s—defeat any claim that urgent intervention is needed to avoid irreparable harm. *See, e.g., Charlesbank Equity Fund*, 370 F.3d at 163 (one-year-long delay); *Channing Bete Co., Inc. v. Greenberg*, 2021 WL 4691597, at *7 (D. Mass. July 12, 2021)

(same) (collecting circuit court cases)); *Media3 Techs., LLC v. Mail Abuse Prevention Sys., LLC*, 2001 WL 92389, at *9 (D. Mass. Jan. 2, 2001) (six-months-long delay); *Loc. 507, Transp. Workers Union of Am., AFL-CIO v. Transp. Workers Union of Am., AFL-CIO*, 2001 WL 92161, at *6 (D. Mass. Jan. 12, 2001) (same). The same should have been true here.

The district court’s conclusion is not only legal error, but sets a dangerous precedent. As Insulet admitted, this case was not about urgently protecting trade secrets at the time they were allegedly misappropriated, but rather about timing a lawsuit to most effectively thwart a merger: “[i]t is one thing for EOFlow to have misappropriated Insulet’s trade secrets,” but “quite another to have that in the hands of Medtronic.” Appx2355. That argument persuaded the district court, but it wrongly divorces the alleged misconduct from the purported irreparable harm. The law stands otherwise for good reason—where trade secret law requires “eternal vigilance,” the district court’s approach invites claimants to ignore misappropriation until a clear and concrete commercial threat materializes. This would encourage inefficiency, gamesmanship, and waste. Where a company like Insulet was “surely aware of” for months if not years of the allegedly infringing “products—and at least generally how they worked— . . . it would seem manifestly unfair to be quick to enter a preliminary injunction against the defendants[.]” *Abbott Lab’ys v. Selfcare, Inc.*, 17 F. Supp. 2d 43, 50 (D. Mass. 1998).

B. Insulet Does Not Face Any Imminent Harm Warranting Preliminary Relief.

“Absent something that indicates a need for *immediate* relief, a plaintiff’s request for a preliminary injunction ordinarily ought to be rejected.” *Matos v. Clinton Sch. Dist.*, 367 F.3d 68, 74 (1st Cir. 2004); *see also Macchione v. Coordinator Adm’r*, 591 F. App’x 48, 50–51 (3d Cir. 2014) (unpublished) (a plaintiff cannot show irreparable harm through an injury that “will occur only in the indefinite future” but “must make a clear showing of *immediate* irreparable harm”) (emphasis in original)); *Winter*, 555 U.S. at 21–22 (rejecting argument that party need only demonstrate “a possibility” of irreparable harm as “too lenient” a standard); *Sierra Club v. Larson*, 769 F. Supp. 420, 422 (D. Mass. 1991) (“[A]n injunction will not be issued to prevent the possibility of some remote future injury.”).

Here, the district court erred in finding irreparable harm because: (1) EOFlow’s acquisition by a larger company is not a proper basis for finding irreparable harm; and (2) Insulet has not shown EOFlow will imminently launch any product in the United States.

1. A Competitor’s Potential Acquisition Does Not Constitute Irreparable Harm.

To secure an injunction, a plaintiff “must do more than demonstrate that it might lose market share as a result of defendant’s infringement.” *Oxford Immunotec Ltd. v. Qiagen, Inc.*, 271 F. Supp. 3d 358, 368 (D. Mass. 2017) (citing *Apple, Inc. v.*

Samsung Elecs. Co., 678 F.3d 1314, 1325 (Fed. Cir. 2012)). The district court acknowledged that, to issue an injunction, it would need to find “something that is immediate that would cause harm that is irreparable.” Appx20. The court held the Medtronic acquisition would qualify because it would provide EOFlow extra capital and expertise. Appx21. But plaintiffs cannot prove irreparable harm by contending they would have to “compete effectively against a giant corporation,” particularly where they “should have been aware” earlier of the potential claim. *Fritz v. Arthur D. Little, Inc.*, 944 F. Supp. 95, 98 (D. Mass. 1996). No irreparable harm arises on such facts because the competitive shift from a “smaller company” to a larger one “is not necessarily any more irreparable,” as the infringement “is not qualitatively different.” *Id.* (citing *Bourne Co. v. Tower Records, Inc.*, 976 F.2d 99, 102 (2d Cir. 1992) (no irreparable harm exists where “the quality of the new harm” was “foreseeable”)); *Abbott Lab’ys v. Andrx Pharm., Inc.*, 452 F.3d 1331, 1348 (Fed. Cir. 2006) (“[W]e do not doubt that generic competition will impact Abbott’s sales of Biaxin XL, but that alone does not establish that Abbott’s harm will be irreparable.”).

Insulet’s argument, and the district court’s decision—that it would be “one thing” to have trade secret misappropriation (which could be safely ignored indefinitely) and “quite another” to have a defendant be acquired by another company (which must be stopped immediately)—is misguided. The purpose of

“[a]n injunction in a trade secret case” is “to protect the secrecy of misappropriated information and to eliminate any unfair head start the defendant may have gained.” *Lamb-Weston, Inc. v. McCain Foods, Ltd.*, 941 F.2d 970, 974 (9th Cir. 1991). Here, it was publicly announced *months ago*, in February 2023, that Medtronic and EOFlow had undertaken significant technical diligence on EOPatch Version 2. Appx945; Appx1071–75. Thus, even if Insulet’s desire to prevent future information-sharing with Medtronic were a valid basis for showing irreparable harm, “that ship has sailed.” *United States v. Booz Allen Hamilton Inc.*, 2022 WL 16553230, at *2 (D. Md. Oct. 31, 2022) (denying preliminary injunction that aimed “to pause [an] acquisition”); *Bridgeview Bank Grp. v. Meyer*, 49 N.E.3d 916, 923 (Ill. App. 2016) (holding that injunctive relief is forward-looking and “cannot remedy misconduct, such as the improper acquisition of trade secrets, that occurred in the past” (quotation omitted)).

2. Insulet Has Not Shown Any Imminent Product Launch in the United States.

As for imminence, the undisputed record shows that even if the Medtronic acquisition proceeded, EOFlow was not “close to marketing a product” in the United States, and any such competitive sales would occur, at the very soonest, years in the future. Appx1750. FDA approval would have to predate any such activity, and EOFlow does not even have a pending application before the FDA, or plans to resubmit one. *Id.*; see *Campbell Soup Co. v. ConAgra, Inc.*, 977 F.2d 86, 92 (3d Cir.

1992) (holding that plaintiff failed to show “immediate irreparable harm based on the marketing of a competing product using the alleged trade secret” because “[t]here was no evidence that [the Defendant] was close to marketing a product based on that technology”); *see also Macchione*, 591 F. App’x at 50–51 (harms that “occur only in the indefinite future” cannot be the basis for preliminary injunctive relief).³

C. Insulet Has Adequate Alternative Remedies at Law.

“To demonstrate irreparable harm, plaintiff must establish that monetary damages would be insufficient.” *Kerrissey v. Com. Credit Grp., Inc.*, 359 F. Supp. 3d 151, 156 (D. Mass. 2019); *see also, e.g., Charlesbank Equity Fund*, 370 F.3d at 162 (similar). EOFlow presented ample expert evidence on this point, but the district court did not even consider this requirement, and Insulet came nowhere close to satisfying it. Expert testimony demonstrates that any harm suffered by Insulet would be quantifiable through a standard damages analysis, such as evaluating any head start gained, development costs avoided, or a reasonable royalty on sales. Appx2028; Appx2032. This is particularly true given the age and lack of continuous use of the information at issue—at most, some of that old information saved EOFlow some time or money, which would be calculable. Insulet does not even contend that

³ In the meantime, the market is shifting away from such devices like Insulet’s Eros and EOFlow’s EOPatch 2, and toward devices that are more compatible with smartphone applications. *See* Appx2029–30; Appx2874 (noting that Insulet will discontinue use of its device on December 31, 2023).

such damages would be impossible to calculate; Insulet’s Executive Vice President testified that Insulet tracked and calculated lifetime value per customer and received monthly prescription data for itself and other competitive companies, conceding that any damages are calculable. Appx2088.

* * *

For all these reasons, the district court committed reversible error in its analysis of irreparable harm.

III. THE BALANCE OF THE EQUITIES AND THE PUBLIC INTEREST WEIGH AGAINST PRELIMINARY INJUNCTIVE RELIEF.

Courts may not issue preliminary injunctions without analyzing “a balance of equities . . . [and] the public interest.” *Arborjet, Inc. v. Rainbow Treecare Sci. Advancements*, 794 F. 3d 168, 171 (1st Cir. 2015). In half a sentence, the district court concluded—based almost entirely on its (erroneous) likelihood-of-success determination—that the balance of equities “favors the issuance of a preliminary injunction,” and that there was “little impact” on the “public interest . . . one way or the other.” Appx22; *cf. Winter*, 555 U.S. at 26 (holding that district abused discretion in granting preliminary injunction by “addressing [the balance of equities and the public interest] in only a cursory fashion,” as “[t]he court’s entire discussion of these factors consisted of one (albeit lengthy) sentence”). The district court not only erred in failing to meaningfully consider these factors—conflating likelihood of success on the merits with an assessment of the equities—but also erred in the result: the

equities and public interest weigh *against* preliminary relief, for three primary reasons.

First, the district court failed to consider Insulet’s delay in acting to protect its alleged trade secrets when considering the equities. *See Bos. Parent Coal. for Acad. Excellence Corp. v. Sch. Comm. of City of Bos.*, 996 F.3d 37, 50 (1st Cir. 2021) (affirming denial of injunction because plaintiff was “sitting on its collective hands” and exacerbated potential harm to others when it “waited over four months”); *Respect Maine PAC v. McKee*, 622 F.3d 13, 16 (1st Cir. 2010) (denying preliminary injunction due to the balance of the harms and public interest because plaintiff waited “six months” and then filed suit shortly before the challenged event, such that the “‘emergency’ [was] largely one of their own making”).

Second, the district court consistently and expressly disregarded harm to EOFlow. *See, e.g.*, Appx7871 (“I am disinclined to give much weight to whatever the financial impact on EOFlow may or may not be under the circumstances from the decision.”). Predictably, the injunction imperiled the Medtronic acquisition, leaving EOFlow with under a year’s capital to operate at its current burn rate. Appx1748. This type of preliminary injunction that would effectively force a company out of business should not issue. *See, e.g., Virginia Carolina Tools, Inc. v. Int’l Tool Supply, Inc.*, 984 F.2d 113 (4th Cir. 1993) (affirming denial of preliminary injunction barring sale of defendant’s business, where injunction might

have “driven [defendant] to insolvency” whereas harm to plaintiff if the sale went through consisted of “highly speculative and largely economic injuries,” such as the “loss of distributor agreements, loss of sales, expenses incurred in relocation, injury to reputation, loss of profits, and loss of volume discounts”); *RE/MAX of New England, Inc. v. Prestige Real Est., Inc.*, 2014 WL 3058295, at *4 (D. Mass. July 7, 2014) (“[T]he balance of the hardships and the public interest both weigh heavily in favor of the defendants. . . . If enjoined, they would effectively have to go out of business.”); *Grease Monkey Int’l, Inc. v. Ralco Lubrication Servs., Inc.*, 24 F. Supp. 2d 120, 125 (D. Mass. 1998) (denying preliminary injunction that would “shut down [the competitor’s] . . . operations”).

Third, the district court’s unorthodox approach—imposing a manufacturing and production injunction that was neither briefed nor requested in either party’s proposed order—deprived the parties of the opportunity to brief a key issue that no one expected to be relevant: the public’s interest in having a choice of medical devices. “[C]ourts are generally reluctant to enjoin the sale of allegedly infringing medicines and medical devices because of the public’s interest in having access to medical treatment.” *Bos. Heart Diagnostics Corp. v. Health Diagnostics Lab’y, Inc.*, 2014 WL 2048436, at *2 (D. Mass. May 16, 2014). Accordingly, while there is no “categorical” rule barring injunctions for “life-saving goods,” *Amgen Inc. v. Sanofi*, 872 F.3d 1367, 1381 (Fed. Cir. 2017), courts have repeatedly declined to impose

preliminary injunctions that would cut off the public’s use of a medical device. *See, e.g., ICU Med. Inc. v. Alaris Med. Sys., Inc.*, 2004 WL 1874992, at *26 (C.D. Cal. July 30, 2004) (denying preliminary injunction because “[p]lacing the public health in jeopardy, by removing potentially life-saving medical devices . . . from the marketplace, is a legitimate factor supporting denial of a preliminary injunction”); *Medtronic MiniMed, Inc. v. Nova Biomedical Corp.*, 2008 WL 11338115, at *4 (C.D. Cal. May 14, 2008) (denying preliminary injunction against “manufacturing, marketing, promoting, or distributing” an allegedly infringing blood glucose meter for an insulin pump because the court would not remove “potentially lifesaving medical devices . . . from the marketplace”); *Vascular Sols. LLC v. Medtronic, Inc.*, 2020 WL 1809195, at *7 (D. Minn. Apr. 9, 2020) (denying preliminary injunction because “the public interest weighs against limiting competition and in favor of permitting the sale of potentially lifesaving medical devices”).

While the district court later made a modest adjustment such that its final, modified order allowed current EOFLOW patients in specific jurisdictions to continue treatment, the damage had been done. Had the district court indicated its intent to issue such an injunction when Insulet had proposed only enjoining further technology transfer to Medtronic, *see* ECF No. 123 (proposed preliminary injunction order), the issue of the public interest would have been front and center, informing the decision to impose any injunction at all. And even as modified, the final order

not only restricts access to the EOfFlow device that exists today, but also prevents EOfFlow and Medtronic’s joint development of a next generation of products premised on EOfFlow’s patented actuator and Medtronic’s sensors and algorithms. Appx2036. In all of these ways, the district court’s final order limits patient choice and prevents new diabetes patients from enjoying the relief to which they would otherwise be entitled.

“The public interest” favors outcomes that promote “the public health.” *World Gym, Inc. v. Baker*, 474 F. Supp. 3d 426, 434 (D. Mass. 2020). And the public is served by advancing “the benefits of fair competition [that] include more choices, better service and the prospect of lower prices.” *Cablevision of Bos., Inc. v. Pub. Imp. Comm’n of City of Bos.*, 38 F. Supp. 2d 46, 63 (D. Mass. 1999) (denying emergency motion for preliminary injunction), *aff’d*, 184 F.3d 88 (1st Cir. 1999). The district court’s order—especially at this preliminary stage—promotes neither competition nor the public health and for this reason, too, the order should be reversed.

CONCLUSION

For the foregoing reasons, this Court should reverse the amended preliminary injunction order below.

Dated: December 4, 2023

COOLEY LLP

/s/ Adam S. Gershenson
ADAM S. GERSHENSON

KIMBERLEY A. SCIMECA
500 Boylston Street
Boston, MA 02116
(617) 937-2300
agershenson@cooley.com
kscimeca@cooley.com

LOWELL D. MEAD
3175 Hanover Street
Palo Alto, CA 94304
(650) 843-5000
lmead@cooley.com

ELIZABETH M. FLANAGAN
30 S. 9th Street, 7th Floor
Minneapolis, MN 55402
(312) 881-6383
bflanagan@cooley.com

PATRICK J. HAYDEN
55 Hudson Yards
New York, NY 10001
(212) 479-6000
phayden@cooley.com

*Counsel for Defendants-Appellants
EOFlow Co., Ltd. and EOFlow, Inc.*

ADDENDUM

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS

INSULET CORPORATION,)
Plaintiff,)
)
)
vs.) Civil Action
)
) No. 23-11780-FDS
EOFLOW CO., LTD.; EOFLOW, INC.;)
FLEX, LTD.; FLEXTRONICS)
CORPORATION; FLEXTRONICS)
MEDICAL SALES AND MARKETING,)
LTD.; LUIS J. MALAVE; STEVEN)
DIIANNI; and IAN G. WELSFORD,)
Defendants.)

BEFORE: CHIEF JUDGE F. DENNIS SAYLOR

STATUS CONFERENCE

John Joseph Moakley United States Courthouse
Courtroom No. 10
1 Courthouse Way
Boston, MA 02210

October 4, 2023
9:00 a.m.

Valerie A. O'Hara
Official Court Reporter
John Joseph Moakley United States Courthouse
1 Courthouse Way
Boston, MA 02210
E-mail: vaohara@gmail.com

1 APPEARANCES:

2 For the Plaintiffs:

3 Goodwin Procter LLP, by ROBERT D. CARROLL, ESQ., ROBERT
4 FREDERICKSON, III, ESQ., and SCOTT T. BLUNI, ESQ., 100 Northern
Avenue, Boston, Massachusetts 02210;

5 Goodwin Procter LLP, by JENNY ZHANG, ATTORNEY, and
6 MATTHEW GINTHER, ESQ., 1900 N Street NW, Washington D.C. 20036;

7 Goodwin Procter LLP, by JAMES P. BREEN, ESQ., 620 Eighth
Avenue, New York, New York 10018;

8 For the Defendants:

9 Cooley LLP, by ADAM S. GERSHENSON, ESQ., and
10 MICHAEL SHEETZ, ESQ., 500 Boylston Street, Boston,
Massachusetts 02116;

11 K&L GATES, by CHRISTOPHER CENTURELLI, ESQ., and
12 MICHAEL R. CRETA, ESQ., 1 Congress Street, Suite 2900,
Boston, Massachusetts 02114-2023.

13 Quinn Emanuel Urquhart & Sullivan, LLP, by WILLIAM D.
14 WEINREB, ESQ., and PATRICK D. CURRAN, ESQ., 111 Huntington
Avenue, Suite 520, Boston, Massachusetts 02199.

15
16
17
18
19
20
21
22
23
24
25

PROCEEDINGS

THE CLERK: All rise. Thank you. You may be seated.
Court is now in session in the matter of Insulet Corporation
vs. EOFlow Co. Ltd, et al, Civil Action Number 23-11780.

Would counsel please identify themselves for the
record, starting with the plaintiff.

MR. CARROLL: Good morning, your Honor, Rob Carroll
from Goodwin Procter.

MR. FREDERICKSON: Robert Frederickson also from
Goodwin Procter.

MR. BLUNI: Scott Bluni from Goodwin Procter.

THE COURT: Good morning.

MR. WEINREB: Good morning, your Honor,
William Weinreb from Quinn Emanuel on behalf of the EOFlow
defendants.

MR. GERSHENSON: Good morning, your Honor,
Adam Gershenson, Cooley LLP on behalf of the EOFlow defendants
and the individual defendants.

MR. CURRAN: And Patrick Curran, Quinn Emanuel on
behalf of the EOFlow defendants and the individuals.

THE COURT: Good morning. All right. This conference
was convened for the purpose of me rendering my ruling on the
motion for a preliminary injunction. To cut to the chase, I'm
going to grant the preliminary injunction, grant the motion in
a specific form to be discussed.

1 I'm not going to issue a written opinion. This
2 transcript will serve as my statement of reasons. As I'm sure
3 you can appreciate, I had a great deal of information coming at
4 me very quickly, and I don't want to delay proceedings any
5 further in terms of rendering my decision, which, obviously,
6 will be an appealable order.

7 As I'm sure you're aware, under Rule 65, in order to
8 obtain a preliminary injunction, the moving party must satisfy
9 a four-part test: It must demonstrate that it has a reasonably
10 likelihood of success on the merits of its claims; that
11 immediate irreparable harm will result if the injunction is not
12 issued; that the balance of equities favors issuance of an
13 injunction; and that the public interest favors it as well.

14 As is normally the case, here, the principal focus is
15 on likelihood of success on the merits and immediate
16 irreparable harm. I'll turn first to the question of whether
17 Insulet, the moving party, has established a reasonable
18 likelihood of success.

19 The principal issue, really, the only issue for
20 present purposes is whether Insulet has established a
21 likelihood of success on its claim for misappropriation of
22 trade secrets under the Defend Trade Secrets Act. There are
23 other claims asserted here, including patent infringement,
24 breach of contract, Chapter 93A, false designation of origin
25 and so on. I'm only going to consider, as I think the parties

1 have, the ETSA claim for these purposes.

2 Here there is very substantial, indeed, strong
3 evidence of misappropriation. EOFlow hired four or engaged
4 four former Insulet employees beginning in June of 2017 with
5 the hiring of Luis Malave, the former chief operating officer
6 and head of R & D at Insulet, followed by Ian Welsford, the
7 former director of regulatory affairs, Steve DiIanni, the
8 former director of mechanical engineering, and Bob Strand, a
9 former senior product development engineer.

11:03AM 10 Those individuals used not only their expertise but
11 also confidential information of Insulet, including what appear
12 to be hundreds, if not more, of Insulet's confidential
13 documents, including CAD file drawings, failure modes and
14 effects analyses, manufacturing protocols and instructions,
15 testing protocols, algorithms, and the like to develop a
16 product for EOFlow, the EOPatch 2 in a very short period of
17 time for very little research and development outlay.

18 Insulet took 20 years and spent, according to its
19 testimony, approximately a billion dollars to develop its pump
11:04AM 20 patch. EOFlow's development time was measured in months and in
21 a relatively small amount of money.

22 There is a dispute as to what precisely are the trade
23 secrets, which I'll return to in a moment, but at least as to
24 some substantial set of information, Insulet took reasonable
25 steps to protect the information. Documents were marked

1 confidential, employees were required to sign nondisclosure or
2 confidentiality agreements, systems were password protected,
3 and the like.

4 The standard for protection, of course, is
5 reasonableness, not perfection, and based on the record, and
6 it's not particularly challenged, I think Insulet took
7 reasonable steps to protect the information in question.

8 I also think there's little doubt that that
9 information falls within the statutory definition of trade
11:05AM 10 secret. Again, it involves CAD drawings, specifications,
11 models, testing, protocols and data, manufacturing
12 instructions, protocols, and so on.

13 Discovery has only been preliminary at this point. I
14 think it would be unfair to require at this stage perfection as
15 to the precise number and contours of the trade secrets at
16 issue.

17 Insulet has focused on eight categories as example.
18 For present purposes, I will do the same. The eight categories
19 are failure modes and effects analyses; cannulus seal design
11:05AM 20 and manufacturing; reservoir; bubble channel; spin coating of
21 the silicon or a lubricant; leak testing of the housing; field
22 sensing occlusion algorithm; and exterior surface finish of the
23 tube nut.

24 As to each of these, some combination of design or
25 manufacturing instructions, manufacturing process, or testing

1 process based on Insulet's confidential information was used.

2 The algorithms presumably were embodied in software.
3 Insulet goes through the specific evidence of misappropriation
4 as to those eight categories in its supplemental brief at pages
5 26 to 28. I won't repeat it here. To a substantial extent,
6 some of that is unchallenged.

7 There is also very substantial evidence that Insulet
8 documents were copied verbatim or nearly verbatim. They may
9 have been reformatted or customized, but they were still
10 essentially identical.

11:07AM

11 And, again, this was done by the former Insulet
12 employees, and, in fact, when Mr. DiIanni needed assistance for
13 assembly processes and automation, having gotten past the
14 design stage, he hired Bob Strand, another former Insulet
15 employee to assist with that.

16 I think it's fair to say that trade secrets for
17 products such as this are not limited to things like design and
18 dimensions and materials, that is something you can measure.
19 It is critical to know why the design and manufacturing is done
20 in a particular way, what happens if you do it differently,
21 what failures and experiments have brought you to this point.

11:07AM

22 Copying something blindly takes you to a certain point
23 but no more, and, of course, it's not just the design but the
24 manufacture, how do you make it, in this case, how do you make
25 it at large scale and at a low price, since the product is

1 intended to be disposable and maintain quality.

2 The quality of the finished product in a medical
3 device is critical. If you don't manufacture it properly, it
4 isn't simply an inferior product, it's a product that can make
5 people sick or kill them.

6 It is, of course, true that a final physical product
7 is intended to be revealed to others. It's true that it can be
8 broken down and to some extent reverse engineered, but there is
9 much more to the product than that, more than mere dimensions.

11:09AM 10 One of the focuses here has been the tolerance
11 requirements of a manufactured product. The product appears to
12 be manufactured entirely out of metal and plastic or some form
13 of polymer.

14 The tolerances for molding a milk jug or a wiffle ball
15 are, of course, quite different from a sophisticated and
16 complex medical device, and as near as I can make out, that's
17 true for virtually every component.

18 And even at the most basic level, things like CAD
19 files, specifications, you can say that you want to copy the
11:09AM 20 dimensions of a particular object, but you would still have to
21 pay someone to do that, to draw and design the product and to
22 develop a manufacturing process, and if you steal the drawings,
23 that's one more way in which you have saved time and money.

24 EOFlow does note that physical features can be reverse
25 engineered, and, of course, that is true to some extent. The

1 mere possibility that something could be reverse engineered
2 without more is not enough to defeat a trade secret claim.

3 There is some evidence, but it's relatively little in
4 the scheme of things as near as I can make out that any of this
5 was actually reverse engineered, and certainly that is not true
6 as to a number of critical components.

7 Reverse engineering is difficult for a sophisticated
8 product such as this. It appears that EOFlow itself was unable
9 to do so before hiring Insulet's former employees and using its
10 documents. Other companies had apparently tried to do so and
11 failed, and, of course, reverse engineering doesn't tell you
12 anything about algorithms, procedures, protocols, and the like.

13 EOFlow notes that because Insulet has patents, it
14 necessarily disclosed information in those patents or patent
15 applications. That's true, but that's, of course, not what
16 we're talking about here.

17 They point out that particular individual components
18 are not novel. That may be true. That's not the standard in a
19 patent case. This is not a patent case. It's how those
20 components taken together as a whole create the product and how
21 it's designed, assembled, and tested.

22 They contend that the information in question is
23 stale. Certainly it could be in the abstract. Some of it was
24 generated considerably a long time ago, but the information is
25 still used. The product is still being manufactured with that

1 information.

2 One might ask if it was not valuable, why was it
3 stolen? It's hardly useless, and even if the product was
4 substantially improved upon over the years, it's a huge start
5 to have the basic information in hand.

6 Similarly, the fact that all of these employees left
7 Insulet long ago could be an issue in terms of the staleness of
8 what they know, but they did take information with them, it was
9 valuable, it was marked confidential, and they used it.

11:12AM 10 And, of course, as has been pointed out, EOFlow
11 engineers did not have medical device experience. A medical
12 device is not the same as a mobile phone, and, again, failure
13 of a phone is not likely to lead to illness or death.

14 EOFlow notes that the fact that the documents may have
15 been on DiIannii's or Welford's computers doesn't necessarily
16 mean that they weren't used or that it could not be attributed
17 to EOFlow unless EOFlow had knowingly benefited from that
18 information. It may be true as to some subset of information.
19 It's hard to tell at this point.

11:13AM 20 Again, the standard for a preliminary injunction is
21 not proof beyond a reasonable doubt. It is certainly possible
22 that there are innocent explanations for some of this. It's
23 certainly possible that DiIanni took documents but never used
24 them, but certainly the evidence to date strongly suggests the
25 contrary, at least in some instances, and the question, again,

1 on a preliminary basis, is there a reasonable likelihood of
2 success on the merits?

3 Again, the specific trade secrets are not only
4 important as of themselves, but because they add up to a whole,
5 this is a medical device, a complex machine. It has to be
6 built to rigorous standards. The value of a small number of
7 secrets that solve critical problems can be greater than the
8 sum of its parts. If this device cannot be made to work
9 reliably or safely, if it can't be built to scale for a
10 competitive price, it isn't worth anything. Again, you don't
11 wind up with a product that is not as good, you wind up with a
12 product that has no value at all.

13 EOFlow appears to have taken the information because
14 it needed it, and having established that a very substantial
15 number of trade secrets were, in fact, misappropriated and
16 were, in fact, used to develop the EOFlow patch pump, it's, I
17 think, unfair under the circumstances to demand a high level of
18 exactitude from Insulet as to precisely what was taken and
19 precisely how it was used that can await further discovery.

11:15AM 20 In short, there is strong evidence that Insulet is
21 likely to succeed on the merits of its trade secrets claim at
22 least in part, and that factor weighs heavily in favor of an
23 injunction.

24 There is substantial evidence, I should add, that the
25 misappropriation was knowingly. Certainly it's true as to the

1 four individuals, and whether they were employees or
2 consultants, they're agents of EOFlow, their conduct is
3 attributable to the principal, and as to Mr. Kim and others at
4 EOFlow, a strong inference can be drawn under the circumstances
5 that they were very much aware that the company was taken
6 advantage of the trade secrets of Insulet.

7 So I find that the first requirement, reasonable
8 likelihood of success on the merits, has been satisfied.

9 The second requirement is immediate irreparable harm.

11:15AM 10 This is the most disputed of the four factors or requirements.
11 Those four factors do not necessarily carry equal weight.
12 Under the case law, when likelihood of success on the merits is
13 great, a movant can show somewhat less in the way of
14 irreparable harm. That's *EEOC vs. Astra USA, Inc.*, 94 F.3d
15 738, (1st Cir. 1996).

16 The irreparable harm test is not applied rigidly.
17 It's often referred to as a sliding scale analysis working in
18 conjunction with the first factor, likelihood of success, and
19 likelihood of success on the merits is always the foremost
11:16AM 20 consideration and weighs most heavily in the analysis.

21 As an initial point in the analysis, the defendants
22 conflate two distinct although at least somewhat overlapping
23 concepts. One is when does a cause of action accrue for
24 purposes of calculating when the limitations period begins to
25 run, and the second is what is undue delay in the context of

1 seeking a preliminary injunction?

2 A cause of action accrues when a party is put on
3 inquiry notice of a possible claim. That does not mean that
4 there are enough facts to file a complaint but sufficient to
5 trigger an inquiry, and from that point forward, you have three
6 or four or five years, whatever the statutory period is, to
7 file a complaint.

8 Immediate irreparable harm is a standard that looks to
9 the immediate future, what is about to change that will cause a
10 harm that cannot be repaired, and what is the immediacy, the
11 urgency? If that state of affairs has existed for some period
12 of time, it undercuts the argument that this is indeed an
13 urgent matter requiring extraordinary relief, or to put it more
14 bluntly, if you didn't think the matter was urgent, why should
15 the Court?

16 In some instances, that casts doubts on the motive of
17 the moving party if such a motion might be interposed for
18 strategic or business reasons, and intertwined with that, I
19 think, is the issue of possible harm or unfairness to the
11:18AM 20 defendant, who -- I'm sorry, to the defendant when the
21 plaintiff sat on its rights. It's a form of laches perhaps,
22 perhaps better analyzed under the balance of equities test, but
23 it's a different inquiry.

24 I also note that not all intellectual property cases
25 are alike for these purposes. Use of a trade name, for

1 example, is obvious as soon as you see it. If you become aware
2 that your company's name is or a same or similar name is being
3 used by another company in a same or similar market, normally
4 you're required to take action immediately. That's why cease
5 and desist letters are used to put the other side on notice,
6 and, in fact, sometimes the conduct is perfectly innocent in
7 the sense that the offending user of the name was not aware
8 another company existed or there was no intent to create
9 customer confusion.

11:19AM 10 Patent cases are also different. It's typical, the
11 company's attempt to design new patents, but a patent is public
12 information, and usually the comparison of the accused product
13 to the claims can be done fairly quickly.

14 Trade secrets, particularly ones that are stolen, are
15 different. It's normally a clandestine matter. You can't file
16 a lawsuit based on mere suspicion or speculation. Inquiry
17 notice is not enough. At some point that has to crystalize
18 into actual evidence sufficient to support a claim, and,
19 obviously, the subsequence is important, the sequence of
11:19AM 20 events. It's important here, and I want to turn to that next
21 and walk through that with some degree of detail.

22 The first event is the American Diabetes Association
23 Trade Show in 2018. According to the evidence, Eric Benjamin,
24 who is the head of R & D at Insulet visited a booth of EOFlow's
25 where one or more devices were displayed.

1 There was certainly evidence that there was a glass
2 case with at least one device with an opaque cover. According
3 to EOFlow, there was also a device with a transparent cover
4 that was available for viewing. There's no photo of that in
5 the record and no actual transparent cover. And, in addition,
6 Jason O'Connor, who was then a senior engineer at Insulet said
7 that he saw Luis Malave, again, the former head of R & D at
8 Insulet, at the conference and learned he was working for
9 EOFlow.

11:21AM 10 Mr. O'Connor says, and it's disputed, that Insulet
11 employees attempted to obtain information from EOFlow
12 unsuccessfully. EOFlow says he was answering questions to
13 anyone who asked, and I think it was O'Connor who said that
14 there was a stunning resemblance to his product. He was, of
15 course, referring to the exterior design, not the interior
16 configuration of the product.

17 According to EOFlow, that put Insulet on inquiry
18 notice, and, that, therefore, the relative time frame for
19 measuring delay begins in 2018. I express no opinion about the
11:21AM 20 accrual of the statute of limitations. That's not the issue
21 here. The question is could Insulet at that point have filed
22 for preliminary injunction? I think the answer to that is no.
23 What would it say? This product looks like ours from the
24 outside and our former R & D head is working there?

25 That is certainly not enough to state a claim. One

1 wonders what inquiry could it have undertaken? The product was
2 not for sale, it was likely a prototype. A prototype is very
3 different from a final product that's available for sale.

4 EOFlow says Insulet should have asked us questions.
5 It's hard to imagine that the likely response would have been,
6 we've taken your trade secrets, or we've hired Mr. Malave in
7 order to get your trade secrets from you, and for that reason,
8 I place very little weight, if any, on the trade show
9 disclosure.

11:22AM 10 I think events really begin at the end of March 2021.
11 There is an Insulet document. I think it's Exhibit 22. There
12 may be more than one Exhibit 22, but it's marked as Exhibit 22,
13 which was basically a technical analysis performed on what
14 appeared to be EOFlow's product. It seems clear to me they did
15 not have a device. It was not available for purchase for
16 another three days and then only in Korea, so it appears to
17 have been based on publicly-available information, whatever was
18 posted online or patent information.

19 It was focused on the actuator, which is different
11:23AM 20 from Insulet's actuator, but throughout the document, which
21 might be expected an examination of where EOFlow seemed to be
22 in terms of producing a product.

23 You see comments like it's at a very early stage,
24 there are manufacturing challenges, safety challenges, design
25 challenges, considerable capital to be required. There's no

1 evidence of depth and customer care support, little development
2 beyond basic availability. Scaling, manufacturing would
3 require a substantial investment and time-consuming automation
4 lasting more than a year.

5 There are things that EOFflow may struggle with,
6 assembly of the actuator will require manufacturing and
7 engineering innovations, and so on.

8 I think the bottom line at that point is Insulet was
9 skeptical that this was a real product that was anywhere near
10 to being placed on the market. It was analyzing not the
11 product but really technical specifications from a distance,
12 that it was a long way from being any kind of meaningful
13 competitor, and, most importantly, there's nothing in the
14 document that suggests an awareness or even a suspicion that
15 Insulet's trade secrets were being used, and there's no real
16 reason for Insulet to have thought otherwise.

17 One of the affidavits, I think it's Mr. Benjamin's,
18 indicated that he learned that the R & D budget was on the
19 order of \$10 to \$15 million. Insulet again says it spent more
20 than a billion dollars. It says that Medtronic spent hundreds
21 of millions of dollars without success to develop a similar
22 product, and there's an exhibit, I think it's Exhibit 40, if
23 I'm reading my notes correctly, that in the second quarter of
24 2022, there were 350 users in Korea, and by the end of 2022,
25 only 1,000 users, all suggesting something that had progressed

1 little beyond a prototype.

2 Insulet, again, as would be expected, monitors the
3 products of its competitors. There are competitive
4 intelligence reports and briefing talking about the design
5 where Insulet thinks EOFlow is. Again, the patch becomes
6 available for purchase on March 29, 2021 only in Korea.

7 Insulet says that they made efforts to obtain one
8 unsuccessfully, that it had no connection to Korean suppliers
9 or physicians. EOFlow disputes that and said it would have
10 been easy to obtain one. I think Insulet also has suggested it
11 may be unlawful to import the product. I don't know whether
12 that's true or not, but, in any event, Insulet did not have a
13 physical copy of the product for at least another few months.

14 In December 2022, this is Exhibit 35, Insulet prepares
15 a competitive intelligence presentation. It talks about
16 EOFlow, says that production is in the early stages with
17 multiple barriers to overcome, that it was an unproven product
18 in the marketplace, there were minimal sales in Korea and
19 Europe.

11:27AM 20 There is one line in that document that says, "The
21 drive and reservoir designs are taken from OPS, EOFlow employs
22 several ex-Insulet employees." That is the first indication or
23 document that says that there was a suspicion of copying, at
24 least among the exhibits that I have seen.

25 And then three or four months later or so, Insulet

1 obtains a physical copy of the product or obtains the physical
2 product. It inspects it in Acton, Massachusetts, and it
3 concludes that it has multiple features that were copied from
4 Insulet.

5 Alter that month, Insulet files a patent suit in
6 Germany. It becomes aware that EOFlow is looking for a
7 partner. There's a dispute about who instigated some very
8 preliminary communications between EOFlow and Insulet. Insulet
9 says that EOFlow was looking to be acquired or looking for a
10 business deal with Insulet, not the other way around, but, in
11 any event, on May 25th, 2023, Medtronic announces an intent to
12 acquire EOFlow for \$735 million, and this lawsuit is filed on
13 August 3rd.

14 According to Insulet, the critical date is May 25th,
15 2023, when Medtronic announced the acquisition. It says that
16 at the time that deal was expected to close in October.
17 Medtronic was a source not only of capital funding but other
18 corporate support, regulatory expertise, manufacturing
19 expertise, customer service capability, and all the other
20 things that come with having a product of this nature on the
21 market.

22 EOFlow contends that the date, obviously, was much
23 earlier, but overall the picture I think is this, that EOFlow
24 had a product at the end of 2022 that was manufactured in very
25 small quantities, apparently to some extent by hand, that it

1 had many technical hurdles to overcome, particularly in
2 developing on a large scale, safely, reliably and cheap enough
3 to be disposable.

4 Again, this is not just any widget. If it doesn't
5 work properly, it can cause injury or death. Insulet believed
6 correctly, I think, that huge amounts of capital and a long
7 time would be required to achieve that, and certainly the
8 product had a number of resemblances to the Insulet product but
9 not until the February 2023 tear-down in Acton is it clear that
10 it's a copy in multiple critical respects.

11 Even then, without a source of funding and other
12 corporate support, it's unclear how imminent the threat was,
13 and the Medtronic purchase obviously crystallized that. This
14 lawsuit was filed on August 18th, after at least a week or two
15 of meeting and conferring.

16 Even then in its initial iteration, much of it was
17 based on circumstantial evidence and reasonable inferences.
18 Discovery has since produced substantial evidence that trade
19 secrets were, in fact, misappropriated, but, as filed, the
20 lawsuit was based largely on circumstantial evidence.

21 Could the lawsuit have been filed more quickly? Sure.
22 That's not really the standard, whether the lawyers should have
23 worked more weekends expediting the suit. The question is is
24 there something about to happen, that is, something that is
25 immediate that would cause harm that is irreparable?

1 What is immediate or reasonably immediate is the
2 acquisition by Medtronic that would be a source of capital for
3 EOFlow, and, again, not just money but all the other things
4 that come with it, regulatory expertise, marketing expertise,
5 manufacturing expertise, customer support networks, the panoply
6 of things that are required to be a real competitor.

7 Put another way, that it's necessary to take a product
8 like this from the bit player or major competitor to go from
9 making devices by hand for the Korean market to being a
11:32AM 10 worldwide competitor.

11 Is that harm irreparable? It would have a variety of
12 competitive impacts. There's a great deal of case law to the
13 effect that losing market share and having your pricing
14 undercut by a competitor who did not have to spend the same
15 time and money on research and development is, in fact,
16 irreparable harm.

17 I note EOFlow argues that there's no real immediacy
18 and no likelihood of -- because there is no likelihood of near
19 term sales in the U.S., they haven't even applied for FDA
11:33AM 20 approval, but as Insulet pointed out, EOFlow is defectively
21 arguing both that the lawsuit was filed too late, and,
22 therefore, there's no immediate irreparable harm, but also that
23 it's filed too early because the product is not about to be
24 sold in the United States.

25 In any event, I find that the standard for immediate

1 irreparable harm has been satisfied, that is, particularly so
2 because the evidence of likely success on the merits is strong.
3 There was a delay in filing the suit from either February to
4 August or March to August. It is not so undue in my opinion as
5 to completely undercut the sense of urgency.

6 Again, the harm is not a couple hundred sales, the
7 harm is loss of significant market share and price
8 undercutting, and there's no obvious unfairness, at least none
9 that's been pointed out to me that I can see in the sense of a
10 laches-type defense that delay unfairly caused EOFlow to change
11 its position, so I find that the second category has been
12 satisfied.

13 The third category is balance of equities. Here, it
14 favors the issuance of a preliminary injunction. Again,
15 Insulet, according to the evidence, appears to have been a
16 victim of the theft of its trade secrets. EOFlow is losing
17 potentially an opportunity to capitalize on that
18 misappropriation.

19 And as to the fourth category, the fourth factor,
20 public interest, I see little impact one way or the other, so,
21 in conclusion, I find that the four-part standard has been
22 satisfied under Rule 65(a) of the Federal Rules of Civil
23 Procedure.

24 I will preliminarily enjoin EOFlow essentially from
25 using or disclosing confidential information of Insulet, that

1 is, the actual wording of that I am still working on. It's
2 going to issue today, but the thrust of it will be that they
3 are not to use the trade secrets defined as confidential
4 information which itself will be defined in its product, and I
5 will, as Insulet has requested, carve out the actuator process.

6 Like any preliminary injunction, there will be a
7 pending trial on the merits. I'm not going to order a forensic
8 audit. It may be sensible to do that, but they are complicated
9 and expensive, and I'm not going to put that in the preliminary
10 injunction order. We can take that up in due course.

11 As you know, Rule 65(c) requires the posting of a bond
12 in an amount that the Court considers proper to pay any costs
13 or damages sustained by a party found to have been wrongly
14 enjoined.

15 EOFlow seeks security in the amount of \$735 million,
16 which is the acquisition price. That seems to me to be
17 obviously inflated. If the PI is reversed, in other words, if
18 they were wrongly enjoined, EOFlow's value presumably remains
19 approximately the same.

11:36AM 20 The principal harm, as near as I can make out, is
21 legal fees on appeal. If Medtronic decides to walk away
22 because it's concerned that EOFlow, in fact, did misappropriate
23 trade secrets, that's the way the cookie crumbles. If
24 Medtronic decides to walk away for other reasons, the value of
25 EOFlow is certainly not zero, which is what the defense

1 requests.

2 So under the circumstances, I'm going to require the
3 posting of a bond in the amount of a million dollars, which I
4 think is proper to pay the reasonably likely costs and damages
5 sustained by EOFlow if they were wrongly enjoined, and, of
6 course, a preliminary injunction is an appealable order, and so
7 presumably if I am incorrect, it will not take several years to
8 reverse my ruling.

9 And I note, of course, that because this is a
10 preliminary injunction order, it can be modified. I am
11 struggling a bit with the framing of it to make sure it's
12 neither over nor under-inclusive, but it can be modified in due
13 course.

14 I'm just going to touch on another couple of matters
15 and then ask counsel for questions, clarifications, or anything
16 else you want to add.

17 I want to convene a scheduling conference on fairly
18 short order to talk about further discovery and motion
19 practice. Unless someone talks me out of it, I think it makes
11:38AM 20 sense to sever the patent claims, possibly even stay them.

21 As you know, litigating patent cases is complex with
22 claim construction proceedings and all the rest of it. I think
23 the immediate focus ought to be on the trade secrets claim and
24 related matters.

25 If it's a trade secrets only case, I think we could

1 find a way to have a reasonably expedited trial in let's say
2 the late winter or early spring of next year is probably a
3 realistic date, depending on the length of the trial, but I
4 don't see that we can do things quite so fast if the patent
5 claims are included.

6 And, again, the specific form of the order will await
7 further tinkering and wordsmithing for me, but it will issue
8 today, and, again, I will require that a one million dollar
9 bond be posted as a condition of enforcing the preliminary
10 injunction.

11:39AM

11 All right. That was a lot delivered at high speed,
12 and it's something of a monotone. Let me pause. Mr. Carroll,
13 anything from you?

14 MR. CARROLL: Just a couple on the scope of the order,
15 your Honor.

16 THE COURT: Yes.

11:40AM

17 MR. CARROLL: I won't belabor the point, but we
18 believe that we tried in our proposed narrowed injunction and
19 our supplemental briefing to make it more narrowly tailored to
20 just those components sort of downstream from the actuator. I
21 will say we said in our briefing, but I think in fairness, the
22 uncertainties -- we think that the misappropriation was
23 substantial and uncontrolled, and we feel to the extent there
24 is uncertainty about the scope of the injunction, and we've
25 cited this on page 38 of our brief, this is from the

1 restatement of unfair competition, uncertainties regarding the
2 scope of injunctive relief are typically resolved against the
3 wrongdoer, and we believe that our proposed injunction fairly
4 embodies that.

5 THE COURT: And I think that's the correct principle.
6 Again, but as we get further into the case, I mean, already
7 we've learned a lot since the case was filed. I would imagine
8 there will be more to be learned, and it may be that the PI
9 needs to be modified because things were reverse engineered or
10 didn't involve -- this is preliminary.

11 MR. CARROLL: Understood, your Honor. Another
12 technical question about the bond.

13 THE COURT: Yes.

14 MR. CARROLL: We had put in our proposed order that
15 the bond should be posted within seven days. I'm not sure that
16 we need actually that much time, but we would ask for a little
17 bit of time. I'm not sure we can do it immediately today.

18 THE COURT: Yes. I think that's reasonable under the
19 circumstances. And I should add, part of the calculus from my
20 standpoint is if, in fact, charges or harm flows from an
21 improperly-issued injunction, Insulet is not a small company,
22 and it might have other resources from which damages could be
23 paid if it comes to that.

24 MR. CARROLL: I think that's fair, your Honor. And,
25 you know, finally, just on the schedule, we think that -- I

1 guess I don't have an answer on our position on the sever or
2 stay of patent claims, but the Court's suggestion of, you know,
3 trial, which I take to be late 2024 or early '25.

4 THE COURT: No, I was thinking trial in early '24 on
5 trade secrets only meaning, there may be satellite claims.

6 MR. CARROLL: To be sure, that would be a fast
7 schedule, but I think we can confer about it and put together a
8 joint --

9 THE COURT: My plan is not to make your lives
10 miserable, but, you know, as with any dispute like this, the
11 faster it's resolved, the better. I have other things on my
12 plate, God knows, but I'm throwing it out as an idea, and I
13 don't think that's doable if the patent claims are intertwined
14 with that, there's just too much to do.

15 MR. CARROLL: Understood, your Honor. So I would
16 propose that we confer with the defendants because we have two
17 sets of defendants and make a proposal to the Court.

18 THE COURT: Of course, another issue, I suppose, is it
19 only against EOFlow? What about Flex and the individual
20 defendants and the rest of it? I can't make that decision now.
21 The more streamlined this is, the more we get to the core of
22 your claims, the faster we can get this resolved.

23 MR. CARROLL: Understood, your Honor. And just to let
24 the Court know, we may be adding Mr. Strand as a defendant, but
25 I don't think that would unduly broaden the scope of what the

1 Court is talking about.

2 THE COURT: All right.

3 MR. CARROLL: Thank you.

4 THE COURT: Mr. Weinreb.

5 MR. WEINREB: Your Honor, just two quick requests.

6 First, we had understood the Court to be suggesting a trial
7 either in early 2024 --

8 THE COURT: Yes.

9 MR. WEINREB: Not 2025?

11:43AM 10 THE COURT: Yes. When you get old, it's hard to
11 remember things like what year is it, the idea being that could
12 we do all this in six months, and, you know, be ready for
13 trial?

14 And, look, I was a partner in a big firm. Believe me,
15 I know both the resources you have and also the challenges you
16 face, okay, and it's easier for me to say, oh, just get this
17 all done and streamline it, but I do think it makes sense. I
18 mean, it may be that, you know, what I am doing here certainly
19 puts EOFlow's future on hold, and I think it's fair to have
11:44AM 20 that resolved if not by the Court of Appeals then, you know, a
21 trial on the merits. I don't want to do that so quickly that
22 it's unfair, but I don't want to have the usual three-year
23 cycle either, I guess is the point that I'm just expressing
24 preliminary thoughts here.

25 MR. WEINREB: I just wanted to clarify what year it

1 was.

2 THE COURT: Yes.

3 MR. WEINREB: The second thing is --

4 THE COURT: March, April, May is probably the
5 realistic time frame I'm talking about.

6 MR. WEINREB: Okay. With respect to the scope of the
7 order, I understand the Court is still working on it. This is
8 a case, you know, a matter where in some respects from the
9 perspective of the EOFlow defendants, the devil is going to be
10 in the details of how that order is written.

11:45AM

11 THE COURT: Yes.

12 MR. WEINREB: So we'd request if the Court is open to
13 it that if we have an opportunity to take a look at the -- that
14 the Court issue a proposed order and we have perhaps overnight
15 to look at it and submit any suggested changes to it by some
16 date and time certain tomorrow so that we're not in a position
17 of having to actually file a motion to modify the PI for what
18 might potentially be some minor adjustments, and then, of
19 course --

11:46AM

20 THE COURT: I asked for, you know, minor supplemental
21 filings.

22 MR. WEINREB: This wouldn't be -- we wouldn't be
23 looking at, you know, big arguments really, it would just be
24 proposed changes --

25 THE COURT: So what's your thought on that? I would

1 require you to, I guess, extend the TRO?

2 MR. CARROLL: That's what I was going to say. We
3 don't think that's necessary. We both briefed this and put in
4 proposed orders, so I think the parties' positions are clear.
5 If we do do that, we'd like an opportunity to respond, not to
6 make it simultaneous filings, and, of course, the TRO would
7 have to be extended for enough time for the Court to consider.

8 THE COURT: Why don't we do this. I will extend the
9 TRO until Friday. I will issue a proposed form of preliminary
10 injunction to which EOFlow can respond by let's say mid-day
11 tomorrow and then you can respond by let's say Friday morning
12 and then whatever form it will issue will be Friday afternoon.
13 Okay. Will that work?

14 MR. CARROLL: Yes, your Honor.

15 MR. WEINREB: Yes, your Honor.

16 THE COURT: All right. I think it's a fair comment to
17 at least give you a chance to point out my screw-ups before
18 they become effective, and it's without prejudice to later
19 modifying it as circumstances may change.

11:47AM 20 Again, Mr. Weinreb, I think -- well, there is a point
21 here is that this -- at some point, it becomes a soup where
22 it's hard to, you know, break out the individual agreements,
23 and it's all put together, and the case law is that the
24 wrongdoer, you know, has to demonstrate at some point, you
25 know, why what he did was, in fact, not wrongful conduct, I

1 guess, I'll put it that way, but we can take that up in due
2 course.

3 All right. Matt, I am out next week. I'm going to
4 call a Rule 16 scheduling conference for the week after.

5 THE CLERK: How about Monday the 16th at 12:00?

6 THE COURT: Monday, the 16th at 12:00 noon. Does that
7 work?

8 MR. CARROLL: That works for the plaintiffs, your
9 Honor.

11:48AM 10 MR. WEINREB: It works for the defendants, your Honor.

11 THE COURT: Okay. I have no idea where we are on
12 initial disclosures, but I would expect to say if they haven't
13 been completed already, they should be completed by some
14 reasonable time going forward. What I'm really looking for is
15 a schedule. The actual expected trial date will depend on a
16 couple of things, most notably my own schedule and how long we
17 think this case will take to try.

18 At the risk of telling you what you already know, it's
19 a lot easier to find one week than two, two weeks than three
11:49AM 20 and so on, but I do think we ought to try to pick a date and
21 block it off.

22 MR. WEINREB: Your Honor, in calculating the trial,
23 should we assume half days or full days?

24 THE COURT: My trial schedule is 9 to 1, but as I like
25 to say, it's a Rya Zobel 9 to 1, which is I meet with the

1 parties at 8:00 or 8:30 in the morning in order to talk about
2 issues and avoid sidebars. I want the witness in the box and
3 questions being asked at 9-0-0 with a stand up and stretch at
4 ten, stand up and stretch at noon and go to one.

5 I will do afternoon sessions as necessary. For what
6 it's worth, in my experience as both a lawyer and a judge, the
7 case moves at exactly the same speed if we are disciplined
8 about it, and among the many advantages for you, the lawyer,
9 are you have time to think at the end of the day, and that
11:50AM 10 makes your presentations crisper, people start jettisoning
11 evidence if they think a point has been proved appropriately
12 and all the rest of it, so, yes, it will be a 9 to 1 schedule,
13 and, you know, we can work on the details later. I think if
14 we're going to do this, I need to block off the time.

15 People are going to have other commitments, maybe you
16 have them already. I will probably block out April school
17 vacation week in Massachusetts because it may affect lawyers or
18 witnesses, but it certainly affects jurors, it makes it harder
19 to impanel because people are doing whatever they're doing, but
11:51AM 20 we can also have a discontinuous trial period, if necessary.

21 And, of course, if this is a mix of legal and
22 equitable claims, we need to think about how we're going to do
23 that as well, but all that's in the future. Right now, let's
24 just set a timetable, discovery, motion practice, something
25 that expedites this within reason recognizing that, you know,

1 typically you can do 90 percent of the work in about 10 percent
2 of the time. It's the maddening details that take all the
3 time, making sure you've produced everything and all that. All
4 right. Anything else, Mr. Weinreb?

5 MR. WEINREB: Not from us, your Honor.

6 THE COURT: I should say, again, our normal Rule 16
7 process is a joint proposal. If can do a joint proposal,
8 that's great, if you can't, you can do individual ones or
9 better yet one document with the different proposals
10 side-by-side.

11:52AM

11 THE CLERK: In person, by video?

12 THE COURT: Let's do it in person. This proceeding
13 is not sealed, today's proceeding is not. For those of you
14 with travel schedules, I will permit hybrid appearances, just
15 make sure Mr. McKillop knows that. For what it's worth, it
16 makes absolutely no difference to me if you are communicating
17 to me, whether arguing the motion or otherwise, whether you're
18 on video or otherwise. Don't worry about that. If you're in
19 San Jose', if you want to appear by video, that's fine with me,
20 it makes no difference to me.

11:53AM

21 All right. I will issue today a brief extension of
22 the TRO and a proposed form of preliminary injunction, and we
23 will reconvene on Monday, October the 16th at 12:00 noon for
24 the scheduling conference.

25 THE CLERK: All rise.

(Whereupon, the hearing was adjourned at 11:52 a.m.)

C E R T I F I C A T E

UNITED STATES DISTRICT COURT)
DISTRICT OF MASSACHUSETTS) ss.
CITY OF BOSTON)

I do hereby certify that the foregoing transcript,
Pages 1 through 34 inclusive, was recorded by me
stenographically at the time and place aforesaid in Civil
Action No. 23-11780-FDS, INSULET CORPORATION vs. EOFLOW CO.,
LTD., et al. and thereafter by me reduced to typewriting and is
a true and accurate record of the proceedings.

Dated October 5, 2023.

s/s Valerie A. O'Hara

VALERIE A. O'HARA
OFFICIAL COURT REPORTER

UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS

INSULET CORPORATION,

Plaintiff,

v.

EOFLOW CO., LTD.; EOFLOW, INC.;
FLEX, LTD.; FLEXTRONICS
CORPORATION; FLEXTRONICS
MEDICAL SALES AND MARKETING,
LTD.; LUIS J. MALAVE; STEVEN
DIIANNI; and IAN G. WELSFORD,

Defendants.

Civil Action No.
23-11780-FDS

PRELIMINARY INJUNCTION

SAYLOR, C.J.

After a hearing, and after careful consideration of the pleadings and record evidence, for good cause shown, and pursuant to Fed. R. Civ. P. 65, the Court hereby preliminarily enjoins defendants EOFlow Co., Ltd. and EOFlow, Inc., (collectively, “EOFlow”), pending trial on the merits in this action, as follows:

1. EOFlow is hereby restrained from manufacturing, marketing, or selling any product that was designed, developed, or manufactured, in whole or in part, using or relying on the Trade Secrets of Insulet Corporation (“Insulet”), as defined in this Order.
2. EOFlow is hereby restrained from disclosing any Trade Secrets of Insulet, as defined in this Order, to any third party, except as may be reasonably necessary for purposes of conducting this litigation, and in accordance with any applicable protective order

of this Court.

3. For purposes of this Order, the term “Trade Secrets” shall mean any and all Confidential Information of Insulet, as defined in this Order, (a) that was copied, downloaded, removed, or otherwise taken from Insulet by Luis J. Malave, Steven DiIanni, Ian Welsford, or Robert Strand, or any other present or former employee or agent of Insulet, or (b) any information that contains, derives from, or incorporates such Confidential Information.
4. For purposes of this Order, the term “Confidential Information” shall mean (a) any and all information or materials that were marked “confidential” by Insulet and (b) any and all CAD files, drawings, or specifications created by Insulet, whether or not they were marked “confidential.”
5. This Order shall specifically apply to the following items relating to EOPatch version 2, among others, to the extent that the Trade Secrets of Insulet were used in their design, development, or creation:
 - (a) design drawings and specifications for each physical component and subassembly;
 - (b) manufacturing and quality-control instructions for each component and subassembly;
 - (c) revision histories and failure modes for each component design;
 - (d) bills of materials and lists of vendor pricing and capabilities for sourcing of components and raw materials;
 - (e) process-validation procedures;
 - (f) specifications for device software, including but not limited to the occlusion

detection algorithm; and

(g) Failure Modes Effects Analyses and Safety Assurance Case.

6. The foregoing restrictions do not apply to (a) any product, manufacturing, or technical information relating to the operation of EOFlow's electric osmotic actuator or (b) any aspect of the EOPatch version 2 that was designed before August 1, 2017; provided, however, that such information does not contain, derive from, or incorporate any Trade Secrets of Insulet.
7. EOFlow shall preserve all Confidential Information of Insulet located on any EOFlow computer system and any computer systems maintained or possessed by Luis Malave, Steven DiIanni, Ian Welsford, or Robert Strand to which EOFlow has reasonable access.
8. Pursuant to Fed. R. Civ. P. 65(d)(2), the restrictions set forth in paragraph 1 apply to any officers, agents, servants, employees, or attorneys of EOFlow, as well as any other persons who are in active concert or participation with any of them.
9. Within seven days of issuance of this order, Insulet shall post a bond in the amount of \$1,000,000.

So Ordered.

/s/ F. Dennis Saylor IV
F. Dennis Saylor IV
Chief Judge, United States District Court

Dated: October 6, 2023, at 10:40 a.m., in Boston, Massachusetts

UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS

_____ INSULET CORPORATION,)	
)	
Plaintiff,)	
)	
v.)	Civil Action No.
)	23-11780-FDS
)	
EOFLOW CO., LTD.; EOFLOW, INC.;)	
FLEX, LTD.; FLEXTRONICS)	
CORPORATION; FLEXTRONICS)	
MEDICAL SALES AND MARKETING,)	
LTD.; LUIS J. MALAVE; STEVEN)	
DIANNI; and IAN G. WELSFORD,)	
)	
Defendants.)	
_____)	

AMENDED PRELIMINARY INJUNCTION

SAYLOR, C.J.

After a hearing, and after careful consideration of the pleadings and record evidence, for good cause shown, and pursuant to Fed. R. Civ. P. 65, the Court hereby preliminarily enjoins defendants EOFlow Co., Ltd. and EOFlow, Inc., (collectively, “EOFlow”), pending trial on the merits in this action, as follows:

1. EOFlow is hereby restrained from manufacturing, marketing, or selling any product that was designed, developed, or manufactured, in whole or in part, using or relying on the Trade Secrets of Insulet Corporation (“Insulet”), as defined in this Order.
2. EOFlow is hereby restrained from disclosing any Trade Secrets of Insulet, as defined in this Order, to any third party, except as may be reasonably necessary for purposes of conducting this litigation, and in accordance with any applicable protective order

of this Court.

3. For purposes of this Order, the term “Trade Secrets” shall mean any and all Confidential Information of Insulet, as defined in this Order, (a) that was copied, downloaded, removed, or otherwise taken from Insulet by Luis J. Malave, Steven DiIanni, Ian Welsford, or Robert Strand, or any other present or former employee or agent of Insulet, or (b) any information that contains, derives from, or incorporates such Confidential Information.
4. For purposes of this Order, the term “Confidential Information” shall mean (a) any and all information or materials that were marked “confidential” by Insulet and (b) any and all CAD files, drawings, or specifications created by Insulet, whether or not they were marked “confidential.”
5. This Order shall specifically apply to the following items relating to EOPatch version 2, among others, to the extent that the Trade Secrets of Insulet were used in their design, development, or creation:
 - (a) design drawings and specifications for each physical component and subassembly;
 - (b) manufacturing and quality-control instructions for each component and subassembly;
 - (c) revision histories and failure modes for each component design;
 - (d) bills of materials and lists of vendor pricing and capabilities for sourcing of components and raw materials;
 - (e) process-validation procedures;
 - (f) specifications for device software, including but not limited to the occlusion

detection algorithm; and

(g) Failure Modes Effects Analyses and Safety Assurance Case.

6. The foregoing restrictions do not apply to (a) any product, manufacturing, or technical information relating to the operation of EOFlow's electric osmotic actuator or (b) any aspect of the EOPatch version 2 that was designed before August 1, 2017; provided, however, that such information does not contain, derive from, or incorporate any Trade Secrets of Insulet.
7. EOFlow shall preserve all Confidential Information of Insulet located on any EOFlow computer system and any computer systems maintained or possessed by Luis Malave, Steven DiIanni, Ian Welsford, or Robert Strand to which EOFlow has reasonable access.
8. Pursuant to Fed. R. Civ. P. 65(d)(2), the restrictions set forth in paragraph 1 apply to any officers, agents, servants, employees, or attorneys of EOFlow, as well as any other persons who are in active concert or participation with any of them.
9. Within seven days of issuance of this Order, Insulet shall post a bond in the amount of \$1,000,000.
10. Notwithstanding the foregoing, Paragraph 1 of this Order shall not apply to the manufacture, sale, or distribution in the Republic of Korea of EOFlow products designed, developed, or manufactured, in whole or in part, using or relying on the Trade Secrets of Insulet; provided, however, that EOFlow (a) may not export such products from the Republic of Korea and (b) may not market or promote such products to prospective or new patients in the Republic of Korea or elsewhere.
11. Notwithstanding the foregoing, and in order to provide a reasonable period of

transition for existing patients, Paragraph 1 of this Order shall not apply to the sale or distribution of EOFlow products designed, developed, or manufactured, in whole or in part, using or relying on the Trade Secrets of Insulet to patients residing in the European Union who were using such products as of October 6, 2023, pursuant to a written prescription or other written order from a physician or other licensed health-care provider. This exception to Paragraph 1 shall expire on May 1, 2024, unless extended by the Court.

12. Notwithstanding the foregoing, Paragraph 1 of this Order shall not apply to distribution or use of EOFlow products designed, developed, or manufactured, in whole or in part, using or relying on the Trade Secrets of Insulet, in clinical trials taking place in the United Arab Emirates that began on or before October 5, 2023, in order to permit the completion of such clinical trials, and not for any other purpose.

So Ordered.

/s/ F. Dennis Saylor IV
F. Dennis Saylor IV
Chief Judge, United States District Court

Dated: October 24, 2023, at 5:40 p.m., in Boston, Massachusetts

FORM 19. Certificate of Compliance with Type-Volume Limitations

Form 19
July 2020

**UNITED STATES COURT OF APPEALS
FOR THE FEDERAL CIRCUIT**

CERTIFICATE OF COMPLIANCE WITH TYPE-VOLUME LIMITATIONS

Case Number: 2024-1137

Short Case Caption: Insulet Corp. v. Eoflow, Co. Ltd.

Instructions: When computing a word, line, or page count, you may exclude any items listed as exempted under Fed. R. App. P. 5(c), Fed. R. App. P. 21(d), Fed. R. App. P. 27(d)(2), Fed. R. App. P. 32(f), or Fed. Cir. R. 32(b)(2).

The foregoing filing complies with the relevant type-volume limitation of the Federal Rules of Appellate Procedure and Federal Circuit Rules because it meets one of the following:

- ☒ the filing has been prepared using a proportionally-spaced typeface and includes 13,613 words.
- ☐ the filing has been prepared using a monospaced typeface and includes _____ lines of text.
- ☐ the filing contains _____ pages / _____ words / _____ lines of text, which does not exceed the maximum authorized by this court's order (ECF No. _____).

Date: 12/04/2023

Signature: /s/ Adam S. Gershenson

Name: Adam S. Gershenson